324 Matching Annotations
  1. Last 7 days
    1. 10

      Case9: No assertion made on age, gender or ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The identified variants were heterozygote in parents.

      CasePresentingHPOs: HP:0005542

      (Prolonged clotting time)

      CaseHPOFreeText: Bleeding time greater than 20 minutes and hematocrit of 38.1%

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: Genetic study of patient was conducted using direct sequencing of entire coding and exon-intron boundaries of the ITGA2B and ITGB3 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1392A>G (p.Pro464Pro)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA500273575

      gnomAD: https://gnomad.broadinstitute.org/variant/17-42458248-T-C

    2. 3

      Case3: No assertion made on age, gender or ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The identified variants were heterozygote in parents.

      CasePresentingHPOs: HP:0000978, HP:0005542

      (Easy bruising, prolonged clotting time)

      CaseHPOFreeText: Bleeding time greater than 20 minutes,

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: Genetic study of patient was conducted using direct sequencing of entire coding and exon-intron boundaries of the ITGA2B and ITGB3 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.401del (p. Glu134GlyfsTer10)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940222

      gnomAD: N/A

    3. 9

      Case9: No assertion made on age, gender or ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The identified variants were heterozygote in parents.

      CasePresentingHPOs: HP:0000978, HP:0000132, HP:0000421,HP:0000979

      (Easy bruising, menorrhagia, epistaxis, purpura)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: Genetic study of patient was conducted using direct sequencing of entire coding and exon-intron boundaries of the ITGA2B and ITGB3 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.189_236del (c.189-319_236del)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940231

      gnomAD: N/A

    4. 12

      Case12: No assertion made on age, gender or ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The identified variants were heterozygote in parents.

      CasePresentingHPOs: HP:0005542

      (Prolonged clotting time)

      CaseHPOFreeText: Bleeding time greater than 20 minutes, Hematocrit of 39.6%

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: Genetic study of patient was conducted using direct sequencing of entire coding and exon-intron boundaries of the ITGA2B and ITGB3 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.842C>T (p.Thr281Ile)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805055

      gnomAD: N/A

    5. 1

      Case1: No assertion made on age, gender, or ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Table 1 states family history is available.

      ParentalGenotype: The identified variants were heterozygote in parents and were not present as homozygote in their healthy members of the family as expected in cases where mutations are deleterious.

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding time is 20 minutes and hematocrit is 35.5%

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: Genetic study of patient was conducted using direct sequencing of entire coding and exon-intron boundaries of the ITGA2B and ITGB3 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.2T>C (p.Met1Thr)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400028186 (c.2T>C)

      gnomAD: N/A

    6. 8

      Case8: No assertion made on age, gender or ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The identified variants were heterozygote in parents.

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: Genetic study of patient was conducted using direct sequencing of entire coding and exon-intron boundaries of the ITGA2B and ITGB3 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.409-3C>G (intronic mutation with no amino acid change)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940224

      gnomAD: N/A

    7. 6

      Case6: No assertion made on age, gender or ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The identified variants were heterozygote in parents.

      CasePresentingHPOs: HP:0005542, HP:0000132, HP:0000421, HP:0000979

      (Prolonged clotting, menorrhagia, epistaxis, purpura)

      CaseHPOFreeText: Bleeding time of 17 minutes, upper GI bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: Genetic study of patient was conducted using direct sequencing of entire coding and exon-intron boundaries of the ITGA2B and ITGB3 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.1990G>T (p.1990G>T)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400033003

      gnomAD: N/A

    8. 14

      Case12: No assertion made on age, gender or ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The identified variants were heterozygote in parents.

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: Genetic study of patient was conducted using direct sequencing of entire coding and exon-intron boundaries of the ITGA2B and ITGB3 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1071dup (p.Arg358AlafsTer47)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940225

      gnomAD: N/A

    9. 2

      Case2: No assertion made on age, gender or ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Table 1 states family history is available.

      ParentalGenotype: The identified variants were heterozygote in parents and were not present as homozygote in their healthy members of the family as expected in cases where mutations are deleterious.

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding time is greater than 20 minutes and prolonged clotting time

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: Genetic study of patient was conducted using direct sequencing of entire coding and exon-intron boundaries of the ITGA2B and ITGB3 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.1658_1660del (p.Ser553del)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA626684826 (p.Ser553del)

      gnomAD: MAF in Latino population: 0.0001158 https://gnomad.broadinstitute.org/variant/17-45369899-TCTC-T

    1. RL

      Case4: Patient RL

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs:

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: The amplification of DNA fragments using PCR and their electrophoretic migration through a denaturing gradient was used to scan the entire coding region, splice site junctions and promoter regions of the GPIIb and GPIIIa genes for all 20 patients in this study

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD: N/A

    2. HLa

      Case3: Patient HLa

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs:

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: The amplification of DNA fragments using PCR and their electrophoretic migration through a denaturing gradient was used to scan the entire coding region, splice site junctions and promoter regions of the GPIIb and GPIIIa genes for all 20 patients in this study

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD: N/A

    3. HLo

      Case2: Patient HLo

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs:

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: The amplification of DNA fragments using PCR and their electrophoretic migration through a denaturing gradient was used to scan the entire coding region, splice site junctions and promoter regions of the GPIIb and GPIIIa genes for all 20 patients in this study

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD: N/A

    4. HMJ

      Case1: Patient HMJ

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs:

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: The amplification of DNA fragments using PCR and their electrophoretic migration through a denaturing gradient was used to scan the entire coding region, splice site junctions and promoter regions of the GPIIb and GPIIIa genes for all 20 patients in this study

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD: N/A

    5. DN

      Case6: Patient DN

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs:

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: The amplification of DNA fragments using PCR and their electrophoretic migration through a denaturing gradient was used to scan the entire coding region, splice site junctions and promoter regions of the GPIIb and GPIIIa genes for all 20 patients in this study

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD N/A

    1. 40-year-old woman

      Case#: 40 yo, Female, W. Turkey

      DiseaseAssertion: Glanzmann Thrombasthenia

      FamilyInfo: Consanguineous (cousins).

      ParentalGenotype: Both carriers.

      CasePresentingHPOs: (HP:0007420) Spontaneous hematomas, (HP:0001892) Abnormal bleeding, (HP:0100608) Metrorrhagia, (HP:0001935) Microcytic anemia, (HP:0034263) Abnormal vaginal bleeding, (HP:0004944) Cerebral aneurysm,

      PlateletAggregation: Hypochromic anemia and a platelet count of 198 × 109/L (normal range 150–400 × 109/L). Platelet aggregometry showed no aggregation after stimulation with collagen (2 and 10 µg/mL), ADP (4 and 10 µmol/L), and epinephrine (8 µmol/L) (norm > 70%), and reduced (42%, Norm > 70%) agglutination after stimulation with ristocetin (1.2 mg/mL).

      CaseHPOFreeText: Received platelet concentrates multiple times as a young adult before dental surgery. Pregnancy, alloantibodies to glycoprotein αIIbβ3 were detected in the patient’s blood. emergency caesarean section was performed in another hospital. Because the patient developed severe bleeding problems, she received two red cell units, two pooled platelet concentrates, tranexamic acid, and desmopressin intraoperatively. Two drainages were placed. Three platelet concentrates were transfused in the following days, resulting in a first-time transfusion reaction. Emergency cesarean- endometrial coagulation, operative hysteroscopy.

      ProteinExpression: Flow cytometry showed the absence of expression of CD41 (integrin αIIbβ3) and severely impaired fibrinogen binding after ADP activation

      CasePreviousTesting: molecular genetic analysis was performed using a custom gene panel for inherited platelet disorders (Nextera Rapid Custom Enrichment, Illumina, San Diego, CA, USA) established in our department, followed by sequencing on a MiSeq (Illumina)

      Gene: ITGA2B

      HGVS: 6138

      ClinVar: Unregistered

      CAID: CA2261369696

      gnomAD: Absent

      Gene: ITGA2B

      HGVS: 6138

      ClinVar: Unregistered

      CAID: CA2261369696

      gnomAD: Absent

  2. www.researchgate.net www.researchgate.net
    1. Patient 2

      Case2: Patient 2, Male, 4 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected brother is Patient 1

      ParentalGenotype: Mother and father revealed heterozygosity for c.1878G>C mutation. (Parents are consanguineous)

      CasePresentingHPOs: HP:0000967 (Petechiae)

      CaseHPOFreeText: Hematomas, prolonged in vitro bleeding time

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis revealed that there was 109 of GPIIb/IIIa expression for Patient 2

      PlateletAggregation: All patients' platelets showed severely reduced platelet aggregation after stimulation with collagen and ADP in contrast to the normal range (See Table 1). Stimulation with epinephrine and arachidonic acid also demonstrated decreased platelet aggregation. In contrast, ristocetin-induced platelet aggregation was borderline for Patient 2

      CasePreviousTesting: Sequenced ITGA2B and ITGB3 genes from one patient of each family (Patient 2 and 3) and Patient 1 and 4 were screened for the identified mutation in the corresponding family.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1878G>C (p.Gln626His)

      LegacyVariant: N/A

      ClinVar: 2903

      CAiD: CA115852

      gnomAD: N/A

    2. Patient 1

      Case1: Patient 1, Male, 6 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected brother is Patient 2

      ParentalGenotype: Mother and father revealed heterozygosity for c.1878G>C mutation. (Parents are consanguineous)

      CasePresentingHPOs: HP:0000967, HP:0000421, HP:0000225

      (Petechiae, epistaxis, gingival bleeding)

      CaseHPOFreeText: Hematomas,

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis showed that there was no surface expression of GPIIb/IIIa detectable on patient 1's platelets, indicating a lack of platelet GPIIb/IIIa expression

      PlateletAggregation: All patients' platelets showed severely reduced platelet aggregation after stimulation with collagen and ADP in contrast to the normal range (See Table 1). Stimulation with epinephrine and arachidonic acid also demonstrated decreased platelet aggregation. In contrast, ristocetin-induced platelet aggregation was within normal range for patient 1

      CasePreviousTesting: Sequenced ITGA2B and ITGB3 genes from one patient of each family (Patient 2 and 3) and Patient 1 and 4 were screened for the identified mutation in the corresponding family.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1878G>C (p.Gln626His)

      LegacyVariant: N/A

      ClinVar: 2903

      CAiD: CA115852

      gnomAD: N/A

    1. GT1

      Case1: (GT1), Gender, age and ethnicity not reported

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: 1 brother and 1 sister that are both heterozygous for g.951G>A and p.Leu343Pro

      ParentalGenotype: Father: heterozygous for g.951G>A and p.Leu343Pro and Mother: heterozygous for both just like dad

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGA2B

      Variant: NC_000017.11:g.44393555C>T (g.951G>A promoter variant) and NM_000419.3:c.1028T>C (p.Leu343Pro)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA913189168 (promoter variant) and CA399804619 (p.Leu343Pro)

      gnomAD N/A

    2. 54

      Case3: (GT54), Gender, age and ethnicity not reported

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: 1 sister that are heterozygous for g.951G>A and p.Leu343Pro

      ParentalGenotype: Father: heterozygous for g.951G>A and p.Leu343Pro and Mother: heterozygous for both just like dad

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGA2B

      Variant: NC_000017.11:g.44393555C>T (g.951G>A promoter variant) and NM_000419.3:c.1028T>C (p.Leu343Pro)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA913189168 (promoter variant) and CA399804619 (p.Leu343Pro)

      gnomAD N/A

    3. GT15

      Case34: (GT15) Gender, age and ethnicity have not been specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Mother and father are heterozygous for this mutation

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1753-1G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399802017

      gnomAD N/A

    4. GT28

      Case16: (GT28) Gender, age and ethnicity is not reported

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Sister is heterozygous for the mutation

      ParentalGenotype: Mother and father are both heterozygous for the mutation

      CasePresentingHPOs:

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGB3

      Variant: NM_000212.2:c.1031A>G (p.Tyr344Cys)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400025816

      gnomAD N/A

    5. GT53

      Case19: (GT53) Gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Has a sister who does not have either of the 2 mutations (normal)

      ParentalGenotype: Father: Does not have the Asp139His mutation but is heterozygous for the Tyr141Cys mutation. Mother: Heterozygous for the Asp139His mutation and is normal or does not harbor the Tyr141Cys mutation

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGB3

      Variant: NG_008332.2:g.35655G>C (p.Asp139His) and NM_000212.2:c.422A>G (p.Tyr141Cys)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400021843 and CA40002188, respectively as shown above

      gnomAD N/A

    6. GT19

      Case36: (GT19) Gender, age and ethnicity are not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: One brother is homozygous for the mutation and the other brother is heterozygous for the mutation

      ParentalGenotype: Mother and father are heterozygous for the mutation

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGA2B

      Variant: There seems to be a typo in this variant, asked Shruthi NM_000419.3:c.937G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290954329

      gnomAD MAF in the European (non-Finnish) population is 0.000008888 https://gnomad.broadinstitute.org/variant/17-42461461-C-T

    7. GT59

      Case32: (GT59) Gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Has one normal borther and one brother who is heterozygous for the mutation

      ParentalGenotype: Both parents are heterozygous for this mutation that the proband harbors

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGB3

      Variant: NM_000212.2:c.155_156delinsTT

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940691

      gnomAD N/A

    8. GT3

      Case18: (GT3) Gender, age and ethnicity are not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Has one brother and sister without the mutation and has one brother that is heterozygous for the variant

      ParentalGenotype: Mother and father are both heterozygous for the mutation

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGB3

      Variant: NM_000212.2:c.2315T>C (p.Leu772Pro)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400034691

      gnomAD MAF in the African population is 0.00006152 https://gnomad.broadinstitute.org/variant/17-45387518-T-C

    9. GT2

      Case14: (GT2), Gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: His sister is heterozygous for this mutation

      ParentalGenotype: Father and mother are both heterozygous for this mutation

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGB3

      Variant: NM_000212.2:c.725G>A (p.Arg242Gln) There is a typo in the paper-- it says that the c. is c.752G>A however it is 725

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA291224896

      gnomAD N/A

    10. GT38

      Case24: (GT38) Gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2338del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940686

      gnomAD N/A

    11. GT23

      Case33: (GT23) Gender, age and ethnicity are not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Both brothers are heterozygous for this mutation and sister is normal

      ParentalGenotype: Father is heterozygous for the NM_000419.3:c.800-2A>T mutation and mother does not harbor this mutation. Mother is heterozygous for the NM_000419.3:c.1210+4A>G mutation and father does not have this mutation.

      CasePresentingHPOs:

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGA2B

      Variant: NM_000419.3:c.800-2A>T and NM_000419.3:c.1210+4A>G

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805150 and CA915940692

      gnomAD N/A

    12. 18

      Case2: GT18, Gender, age, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: 1 brother is heterozygous for the g.951G>A promoter variant and does not have the other Leu343Pro mutation and one brother is normal and does not have the NM_000419.3:c.2915dup mutation

      ParentalGenotype: Father: homozygous for the g.951G>A promoter variant and the Leu343Pro Mother: is heterozyous for both those mutations and mother does not have NM_000419.3:c.2915dup while the father is heterozygous for NM_000419.3:c.2915dup

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGA2B

      Variant: NC_000017.11:g.44393555C>T (g.951G>A promoter variant) and NM_000419.3:c.1028T>C (p.Leu343Pro) and NM_000419.3:c.2915dup

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA913189168 (promoter variant) and CA399804619 (p.Leu343Pro) and CA8602531

      gnomAD MAF in the East Asian population is 0.0001088 https://gnomad.broadinstitute.org/variant/17-42452054-C-CG for the NM_000419.3:c.2915dup variant

    1. Patient‐III6

      Case2: Female, Israeli-Arab, (age is either 3 or 8)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Fig 1C for pedigree

      ParentalGenotype: See Fig 1C for pedigree

      CasePresentingHPOs: HP:0000421, HP:0031364, HP:0000967, HP:0002239

      (Severe epistaxis, ecchymosis, petechiae, GI bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: No surface expression of αIIbβ3 was found in patients’ platelets (See Fig 3)

      PlateletAggregation: N/A

      CasePreviousTesting: DNA fragments containing exons and flanking intronic regions of the aIIb and B3 genes were amplified by PCR using primers

      Gene: ITGA2B

      Variant: NM_000419.3:c.97A>G (p.Asn2Asp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399806951

      gnomAD: N/A

    2. Patient‐III4

      Case1: Male, Israeli-Arab, (age is either 10 or 14)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Fig 1C for pedigree

      ParentalGenotype: See Fig 1C for pedigree

      CasePresentingHPOs: HP:0000421, HP:0031364, HP:0000967

      (Severe epistaxis, ecchymosis, petechiae)

      CaseHPOFreeText: Decline of hemoglobin levels to 5 g dl each time epistaxis occurred

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: No surface expression of αIIbβ3 was found in patients’ platelets (See Fig 3)

      PlateletAggregation: N/A

      CasePreviousTesting: DNA fragments containing exons and flanking intronic regions of the aIIb and B3 genes were amplified by PCR using primers

      Gene: ITGA2B

      Variant: NM_000419.3:c.97A>G (p.Asn2Asp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399806951

      gnomAD: N/A

    1. Patient 3

      Case3: Male, 10 years old, Korean

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Figure 1 shows haplotype analysis

      CasePresentingHPOs: HP:0001342

      (Cerebral hemorrhage)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analyses revealed decreased expression at 7.2%/5.0% of the normal amount of CD41/CD61

      PlateletAggregation: Platelet aggregation tests were performed to evaluate responses to ADP, collagen, epinephrine, and ristocetin agonists

      CasePreviousTesting: Polymerase chain reaction for all exons ofITGA2Band/orITGB3were performed using primers. Sequence analysis was performed with reference to M_000419.3 andNP_000410.2 forITGA2Band NM_000212.2 and NP_000203.2 for ITGB3.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2333A>C (p.Gln778Pro) and NM_000419.3:c.975del

      LegacyVariant: N/A

      ClinVar: 225393

      CAiD: CA290947544 and CA915940385

      gnomAD: MAF in the East Asian population is 0.0001087 http://gnomad.broadinstitute.org/variant/17-42453691-T-G

    2. Patient 4

      Case4: Male, 4 years old, Korean

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Figure 1 shows haplotype analysis

      CasePresentingHPOs: HP:0000978, HP:0000967

      (Easy bruising, petechiae)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analyses revealed decreased expression at a level of 7.5%(type II GT)

      PlateletAggregation: Platelet aggregation tests were performed to evaluate responses to ADP, collagen, epinephrine, and ristocetin agonists

      CasePreviousTesting: Polymerase chain reaction for all exons of ITGA2Band/orITGB3were performed using primers. Sequence analysis was performed with reference to M_000419.3 andNP_000410.2 for ITGA2B and NM_000212.2 and NP_000203.2 for ITGB3.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2333A>C (p.Gln778Pro) and NM_000419.3:c.1750C>T (p.Arg584Ter)

      LegacyVariant: N/A

      ClinVar: 225393 and 2892

      CAiD: CA290947544 and CA115834

      gnomAD: MAF in the East Asian population is 0.0001087 http://gnomad.broadinstitute.org/variant/17-42453691-T-G and MAF in the East Asian population is 0.0002176 http://gnomad.broadinstitute.org/variant/17-42457372-G-A

    1. GT15

      Case15: GT-15, German, gender or age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Mother: c.1594T>C heterozygous and Father: n/a

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms are severe (See Table 1) Abstract mentions patients' bleeding signs include epistaxis, mucocutaneous bleeding, haematomas, petechiae, GI bleeding and menorrhagia; however, not specified per proband.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry was performed and expression is stated as pathogenic in Table 1

      PlateletAggregation: Platelet aggregation was performed and is stated as pathogenic in Table 1; however, no specific agonists mentioned

      CasePreviousTesting: All exons of ITGA2B and ITGB3 genes as well as surrounding intron regions were amplified by PCR using intronic primers as pre-viously described (12). The purified DNA fragments were then di-rectly sequenced.

      Gene: ITGB3

      Variant: NM_000212.2:c.1594T>C and NM_000212.2:c.2014+1G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400029953 and CA400033055

      gnomAD: N/A

    2. GT10

      Case10: GT-10, Caucasian, gender or age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Mother: 3091delC heterozygous and Father: c.1210_105A>G heterozygous

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms are severe and bleeding time is pathogenic (See Table 1) Abstract mentions patients' bleeding signs include epistaxis, mucocutaneous bleeding, haematomas, petechiae, GI bleeding and menorrhagia; however, not specified per proband.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry was performed and expression is stated as pathogenic in Table 1

      PlateletAggregation: Platelet aggregation was performed and is stated as pathogenic in Table 1; however, no specific agonists mentioned

      CasePreviousTesting: All exons of ITGA2B and ITGB3 genes as well as surrounding intron regions were amplified by PCR using intronic primers as pre-viously described (12). The purified DNA fragments were then di-rectly sequenced.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1210+105A>G and NM_000419.3:c.3091del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290953790 and CA915940322

      gnomAD: N/A

    3. GT2

      Case2: GT-2, German, gender or age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Mother: c.31T>C heterozygous and Father: c.1458T>C heterozygous

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms are severe and bleeding time is pathogenic (See Table 1) Abstract mentions patients' bleeding signs include epistaxis, mucocutaneous bleeding, haematomas, petechiae, GI bleeding and menorrhagia; however, not specified per proband.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry was performed and expression is stated as pathogenic in Table 1

      PlateletAggregation: Platelet aggregation was performed and is stated as pathogenic in Table 1; however, no specific agonists mentioned

      CasePreviousTesting: All exons of ITGA2B and ITGB3 genes as well as surrounding intron regions were amplified by PCR using intronic primers as pre-viously described (12). The purified DNA fragments were then di-rectly sequenced.

      Gene: ITGB3

      Variant: NM_000212.2:c.31T>C and for the second variant c.1458T>C -this does not show up in ensembl it says that the actual alleles are C>T

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA291240306

      gnomAD: N/A

    4. GT8 

      Case8: GT-8, Caucasian, gender or age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Mother: none and Father: c.118C>T heterozygous

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms are moderate (See Table 1) Abstract mentions patients' bleeding signs include epistaxis, mucocutaneous bleeding, haematomas, petechiae, GI bleeding and menorrhagia; however, not specified per proband.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry was performed and expression is stated as pathogenic in Table 1

      PlateletAggregation: Platelet aggregation was performed and is stated as pathogenic in Table 1; however, no specific agonists mentioned

      CasePreviousTesting: All exons of ITGA2B and ITGB3 genes as well as surrounding intron regions were amplified by PCR using intronic primers as pre-viously described (12). The purified DNA fragments were then di-rectly sequenced.

      Gene: ITGB3

      Variant: NM_000212.2:c.118C>T

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400031679

      gnomAD: N/A

    5. GT9

      Case9: GT-9, Caucasian, gender or age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Mother: c.1186G>A heterozygous and Father: c.3060_2T>C heterozygous

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms are severe (See Table 1) Abstract mentions patients' bleeding signs include epistaxis, mucocutaneous bleeding, haematomas, petechiae, GI bleeding and menorrhagia; however, not specified per proband.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry was performed and expression is stated as pathogenic in Table 1

      PlateletAggregation: Platelet aggregation was performed and is stated as pathogenic in Table 1; however, no specific agonists mentioned

      CasePreviousTesting: All exons of ITGA2B and ITGB3 genes as well as surrounding intron regions were amplified by PCR using intronic primers as pre-viously described (12). The purified DNA fragments were then di-rectly sequenced.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1186G>A and NM_000419.3:c.3060+2T>C

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399804315 and CA290944108

      gnomAD: MAF in the South Asian population is 0.00006622 http://gnomad.broadinstitute.org/variant/17-42460885-C-T and MAF in the European non-Finnish population is 0.00003876 http://gnomad.broadinstitute.org/variant/17-42451720-A-G

    6. GT11

      Case11: GT-11, Arab, gender or age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Mother: c.3092delT heterozygous and Father: deceased

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms are severe (See Table 1) Abstract mentions patients' bleeding signs include epistaxis, mucocutaneous bleeding, haematomas, petechiae, GI bleeding and menorrhagia; however, not specified per proband.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry was performed and expression is stated as pathogenic in Table 1

      PlateletAggregation: Platelet aggregation was performed and is stated as pathogenic in Table 1; however, no specific agonists mentioned

      CasePreviousTesting: All exons of ITGA2B and ITGB3 genes as well as surrounding intron regions were amplified by PCR using intronic primers as pre-viously described (12). The purified DNA fragments were then di-rectly sequenced.

      Gene: ITGA2B

      Variant: NM_000419.3:c.641T>C and NM_000419.3:c.3092delT

      LegacyVariant: N/A

      ClinVar: 2901

      CAiD: CA115848 and CA915940323

      gnomAD: N/A

    1. 54-year old female patient with well characterized GT

      Case1: 54 year old, Female

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0003540, HP:0031126

      (Defective platelet aggregation, impaired clot retraction)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed significantly reduced (6-7%) surface expression levels of both aplhaIIb and beta3.

      PlateletAggregation: Light transmission aggregometry in platelet-rich plasma demonstrated an impaired platelet aggregation with all agonists (arachidonic acid, thromboxane receptor agonist U46619, ADP, collagen, epinephrine) except ristocetin.

      CasePreviousTesting: N/A

      Gene: ITGB3

      Variant: NM_000212.2:c.1407dup (p.Asn470Ter) and NM_000212.2:c.1814G>A (p.Gly605Asp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400032596 (p.Gly605Asp) and CA915940250 (p.Asn470Ter)

      gnomAD: N/A

    1. Our patient

      Case#: 4 mo, Female

      DiseaseAssertion: GT

      CasePresentingHPOs: (HP:0001892) Abnormal bleeding; (HP:0000978) Bruising susceptibility

      PlateletAggregation: Severe platelet refractoriness. Pretransplant evaluation revealed normal platelet count. Day +9, the patient had undetectable platelet count. Bleeding-control strategies included the use of thrombopoietin receptor agonist, romiplostim, and low-rate continuous platelet transfusion. Imlifidase was well tolerated with no side effects.

      CaseHPOFreeText: Escherichia coli bacteremia.

      ProteinExpression: Platelet GP expression testing confirmed the absence of platelet GPIIb/IIIa expression. Day +12 confirmed the presence of anti-GPIIb/IIIa antibodies among others.

      Gene: ITGB3

      HGVS: NM_000212.3:c.1788del

      ClinVar:

      CAID: CA2262611500

      gnomAD: 0 https://gnomad.broadinstitute.org/variant/chr17-47299404-GC-G?dataset=gnomad_r4

    1. TE

      Case20: Patient TE, gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: Article states, "heterozygous parents of TE"

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who had minor symptoms, such as epistaxis or gum bleeds, and moderate bleeders suffered, in addition, from bleeding complications after surgery and trauma. Severe bleeders were defined as those with a history of spontaneous or life-threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusion. See Table 1.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 6

      PlateletAggregation: See Table 6

      CasePreviousTesting: To ascertain the mutations, we sequenced the coding regions of the αIIb and β3 subunits including the exon/intron boundaries

      Gene: ITGB3

      Variant: NM_000212.2:c.856G>A (p.Gly286Arg) and the variant is c.1129Ains --> NM_000212.2:c.1129dup

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400020688 and CA915940291

      gnomAD: MAF in the European (non-Finnish) population is 0.00001760 https://gnomad.broadinstitute.org/variant/17-45364514-G-A

    2. LN

      Case16: Patient LN, gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: Parents are heterozygous for mutation (LH and LB)

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who had minor symptoms, such as epistaxis or gum bleeds, and moderate bleeders suffered, in addition, from bleeding complications after surgery and trauma. Severe bleeders were defined as those with a history of spontaneous or life-threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusion. See Table 1.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 6

      PlateletAggregation: See Table 6

      CasePreviousTesting: To ascertain the mutations, we sequenced the coding regions of the αIIb and β3 subunits including the exon/intron boundaries

      Gene: ITGA2B

      Variant: NM_000419.3:c.3062T>C

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399787956

      gnomAD: N/A

    1. Patient C

      Case: (Patient C), Male, age, and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: 2 siblings (compound heterozygotes for the p.Cys674Arg and p.Ile374Thr mutation)

      ParentalGenotype: Mother: (p.Ile374Thr) and Father: (p.Cys674Arg)

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: By immunoblot analysis, it was found that the platelets of the patient and his 2 siblings contained both αIIb and β3, but at reduced levels compared with a healthy control (Figure 1B)

      CasePreviousTesting: Direct sequence analysis of the of the genes encoding αIIb were performed on DNA isolated from leukocytes obtained from Patient C and family members.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1214T>C (p.Ile405Thr) and NM_000419.3:c.2113T>C (p.Cys705Arg)

      LegacyVariant: (p.Ile374Thr) and (p.Cys674Arg)

      ClinVar: N/A

      CAiD: CA290950815 and CA8602816

      gnomAD: MAF in the European (non-Finnish) population is 0.000008792 https://gnomad.broadinstitute.org/variant/17-42455140-A-G

    2. Patient M

      Case: (Patient M) Gender, age, ethnicity are not specified

      DiseaseAssertion: Glanzmann thrombasthenia (diagnosed at 1 year old)

      FamilyInfo: N/A

      ParentalGenotype: Mother: (p.Val298Phe) and Father: (p.Tyr380Ter)

      CasePresentingHPOs: (Went to Reference #17 to see what lab findings/phenotypes were reported for this patient; however, access not available to this article)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: By immunoblot analysis, both αIIb and β3 subunits were detected in the patient's platelet lysates, but at reduced levels compared to a healthy control and samples from both parents (Figure1A)

      CasePreviousTesting: Direct sequence analysis of the of the genes encoding αIIb were performed on DNA isolated from leukocytes obtained from Patient M and family members

      Gene: ITGA2B

      Variant: NM_000419.3:c.985G>T (p.Val329Phe) and NM_000419.3:c.1232dup (Tyr411Ter)

      LegacyVariant: (p.Val298Phe) and (p.Tyr380Ter)

      ClinVar: N/A

      CAiD: CA399804719 and CA915940593

      gnomAD: MAF in the South Asian population is 0.0001312 https://gnomad.broadinstitute.org/variant/17-42458407-G-A

    1. M8

      Case8: Patient M8, Male, French Gypsy, age is not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Figure 2 for pedigree

      ParentalGenotype: Unaffected parents see pedigree Fig 2

      CasePresentingHPOs: N/A

      CaseHPOFreeText: France, GT is particularly frequent in the Gypsy population, mainly represented by the Manouche tribe. Their clinical phenotype is the same as for classic type I disease, with a moderate and occasional severe bleeding syndrome

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis has shown that these patients' surface expresses <5% of normal GPIIIa and GPIIb levels (we are not given an exact value for each proband)

      PlateletAggregation: "Absent platelet aggregation" this is all the information we are given for platelet aggregation

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD: N/A

    1. The propositus is a 40-year-old French male

      Case1: Male, 40 years old, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Mild bleeding symptoms have been reported in his grandmother and a first cousin, but they were not available for further study

      ParentalGenotype: The mother is asymptomatic; however, genetic testing confirmed her to be heterozygous for the GT mutation (No information on father's genetic information for this mutation)

      CasePresentingHPOs: HP:0000225

      (Gingival bleeding)

      CaseHPOFreeText: Very mind bleeding

      CaseNotHPOs: HP:0000421, HP:0000978

      (Epistaxis, bruising)

      CaseNotHPOsFreeText: N/A

      ProteinExpression: The surface expression of GPIIb-IIIa was about 20% of normal, whereas GPIb (93%) was normally expressed (See Figure 1A)

      PlateletAggregation: Platelet aggregation was markedly impaired in response to physical agonists including: ADP, arachidonic acid, epinephrine, and collagen; however, ristocetin induced normal aggregation

      CasePreviousTesting: All 30 exons and immediate flanking sequences of the GPIIb gene, and all 15 exons and immediate flanking sequences of the GPIIIa gene, were amplified by PCR.

      Gene: ITGB3

      Variant: NM_000212.2:c.1756T>C (p.Cys586Arg)

      LegacyVariant: (p.Cys560Arg)

      ClinVar: N/A

      CAiD: CA400032477

      gnomAD: N/A

    1. paternal uncle

      Case3: Male, age not specified, Cypriot (paternal uncle of 3 year old)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Brother and brother's daughter were also affected with same mutation (See Figure 3 for family pedigree)

      ParentalGenotype: Parents were heterozygous for same mutation (See Figure 3 pedigree)

      CasePresentingHPOs: HP:0000225, HP:0000421, HP:0031364

      (Gingival bleeding, epistaxis, ecchymosis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed decreased surface expression of αIIb and β3 in patients' platelets

      PlateletAggregation: Absent platelet aggregation in response to ADP, epineprhine, collagen but normal ristocetin induced platelet aggregation

      CasePreviousTesting: SSCP analysis of the αIIb gene in the three patients revealed an altered pattern of migration of the DNA fragment containing exons 5 and 6 and their flanking intronic regions.

      Gene: ITGA2B

      Variant: M_000419.3:c.605T>G (p.Phe202Cys)

      LegacyVariant: (p.Phe171Cys) + 31= (p.Phe202Cys)

      ClinVar: N/A

      CAiD: CA399805605

      gnomAD: N/A

    2. her father

      Case2: Male, age not specified, Cypriot (father of 3 year old)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Daughter and brother were also affected with same mutation (See Figure 3 for family pedigree)

      ParentalGenotype: Parents were heterozygous for same mutation (See Figure 3 pedigree)

      CasePresentingHPOs: HP:0000225, HP:0000421, HP:0031364

      (Gingival bleeding, epistaxis, ecchymosis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed decreased surface expression of αIIb and β3 in patients' platelets

      PlateletAggregation: Absent platelet aggregation in response to ADP, epineprhine, collagen but normal ristocetin induced platelet aggregation

      CasePreviousTesting: SSCP analysis of the αIIb gene in the three patients revealed an altered pattern of migration of the DNA fragment containing exons 5 and 6 and their flanking intronic regions.

      Gene: ITGA2B

      Variant: M_000419.3:c.605T>G (p.Phe202Cys)

      LegacyVariant: (p.Phe171Cys) + 31= (p.Phe202Cys)

      ClinVar: N/A

      CAiD: CA399805605

      gnomAD: N/A

    3. A 3‐year‐old Cypriot girl

      Case1: Female, 3 years old, Cypriot

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Father and paternal uncle were also affected with same mutation (See Figure 3 for family pedigree)

      ParentalGenotype: Father is homozygous for the mutation and the mother is heterozygous for the mutation (See Discussion)

      CasePresentingHPOs: HP:0000225, HP:0000421, HP:0031364

      (Gingival bleeding, epistaxis, ecchymosis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed decreased surface expression of αIIb and β3 in patients' platelets

      PlateletAggregation: Absent platelet aggregation in response to ADP, epineprhine, collagen but normal ristocetin induced platelet aggregation

      CasePreviousTesting: SSCP analysis of the αIIb gene in the three patients revealed an altered pattern of migration of the DNA fragment containing exons 5 and 6 and their flanking intronic regions.

      Gene: ITGA2B

      Variant: NM_000419.3:c.605T>G (p.Phe202Cys)

      LegacyVariant: (p.Phe171Cys) + 31= (p.Phe202Cys)

      ClinVar: N/A

      CAiD: CA399805605

      gnomAD: N/A

    1. RM

      Case1: (Patient RM) Male, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Mother: heterozygous for (p.Arg724Ter)

      CasePresentingHPOs:

      CaseHPOFreeText: HP:0000978 (Easy bruising)

      CaseNotHPOs: Recurrent mucosal bleeding

      CaseNotHPOFreeText: N/A

      ProteinExpression: Flow cytrometric analysis revealed reduced levels of alphaIIbbeta3 on the surface of RM platelets (See Fig 1B)

      PlateletAggregation: Ristocetin induced agglutination was normal; however, platelets failed to aggregate in response to all physiological agonists including ADP, collagen, epinephrine, thrombin, and arachidonic acid

      CasePreviousTesting: Direct DNA sequence analysis of PCR amplified ITGA2B and ITGB3 genes from patient RM's genomic DNA was performed. All exons, including the immediate intron-exon junctions of ITGA2B and ITGB3 were amplified using the PCR primer pairs originating in the intron sequence flanking each exon. The resulting PCR fragments were purified and subjected to direct cycle sequencing

      Gene: ITGB3

      Variant: NM_000212.2:c.2248C>T (p.Arg750Ter) and NM_000212.2:c.1791del (p.Asn597Lysfs*72)

      LegacyVariant: (p.Arg724Ter)

      ClinVar: 13564

      CAiD: CA123246 and CA8623358

      gnomAD: MAF in the African population is 0.0006008 https://gnomad.broadinstitute.org/variant/17-45384950-C-T

      PreviouslyPublished: PMID: 15701721

  3. watermark.silverchair.com watermark.silverchair.com
    1. The proband is a 20-year-old Caucasian woman

      Case1: Female, 20 years old, Caucasian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See pedigree in Fig 2

      ParentalGenotype: Parental genotype given see Fig 2

      CasePresentingHPOs: HP:0000978 (Easy bruising)

      CaseHPOFreeText: Mucocutaneous bleeding, menstrual hemorrhages

      CaseNotHPOs: N/A

      ProteinExpression: The absence of platelet GPIIb-IIIa complexes by flow cytometric analysis with MoAbs was performed and shown

      Platelet Aggregation: No response detected either spontaneously or in response to agonists (this is all of the information we are given)

      CasePreviousTesting: GPIIb and GPIIIa genes were screened for mutations by SSCP of PCR amplified exons from genomic DNA

      Gene: ITGB3

      Variant: NM_000212.2:c.1924G>T (p.Glu642Ter)

      LegacyVariant: (p.Glu616Ter)

      ClinVar: 13565

      CAiD: CA123249

      gnomAD N/A

    1. GT-13

      Case13: GT-13, gender, age, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: Segregation analysis confirmed the presence of heterozygous mutations in carrier parents

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Article mentions patients presented with variable bleeding diathesis and Table 1 shows the several phenotypes that were seen among the cohort of 13 patients in this study (this article does not state a specific bleeding phenotype for each proband) "Most of the patients had gross blood loss due to epistaxis (54%), cutaneous bleeding (58%) and menorrhagia (100% of women), while other common symptoms (oral cavity, gastrointestinal, following dental extraction or mild injuries, postpartum, or hematomas) were in general milder."

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% of αIIbβ3 expression

      PlateletAggregation: Article mentions the disorder was indentified by platelet testing consisting in severely impaired aggregation in response to all physiological agonists and also TMA (See Table 4). Ristocetin-induced platelet aggregation was normal or reduced to some extent.

      CasePreviousTesting: To detect mutations in ITGA2B or ITGB3, total RNA from peripheral blood was used for cDNA synthesis for RT-PCR. Using specific oligonucleotides and conditions, they amplified and sequenced ITGA2B and ITGB3 by Sanger sequencing, and every mutation found in cDNA was confirmed on DNA samples

      Gene: ITGA2B

      Variant: (p.Trp51Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: Unregistered Variant

      gnomAD: N/A

    2. GT-11

      Case11: GT-11, gender, age, ethnicity not specified

      DiseaseAssertion: Glanzmann thromasthenia

      FamilyInfo: N/A

      ParentalGenotype: Segregation analysis confirmed the presence of heterozygous mutations in carrier parents

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Article mentions patients presented with variable bleeding diathesis and Table 1 shows the several phenotypes that were seen among the cohort of 13 patients in this study (this article does not state a specific bleeding phenotype for each proband) "Most of the patients had gross blood loss due to epistaxis (54%), cutaneous bleeding (58%) and menorrhagia (100% of women), while other common symptoms (oral cavity, gastrointestinal, following dental extraction or mild injuries, postpartum, or hematomas) were in general milder."

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed this proband classified as variant GT (50% expression but receptor being not functional according to LTA and clot retraction)

      PlateletAggregation: Article mentions the disorder was indentified by platelet testing consisting in severely impaired aggregation in response to all physiological agonists and also TMA (See Table 4). Ristocetin-induced platelet aggregation was normal or reduced to some extent.

      CasePreviousTesting: To detect mutations in ITGA2B or ITGB3, total RNA from peripheral blood was used for cDNA synthesis for RT-PCR. Using specific oligonucleotides and conditions, they amplified and sequenced ITGA2B and ITGB3 by Sanger sequencing, and every mutation found in cDNA was confirmed on DNA samples

      Gene: ITGB3

      Variant: NM_000212.2:c.647A>G (p.Tyr216Cys) and NM_000212.2:c.665T> (Leu222Pro))

      LegacyVariant: (p.Tyr190Cys) and (p.Leu196Pro)

      ClinVar: N/A

      CAiD: CA400023432 and CA291224887

      gnomAD: N/A

      PreviouslyPublished: 11897046 (p.Leu196Pro)

    3. GT-10

      Case10: GT-10

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Segregation analysis confirmed the presence of heterozygous mutations in carrier parents

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Article mentions patients presented with variable bleeding diathesis and Table 1 shows the several phenotypes that were seen among the cohort of 13 patients in this study (this article does not state a specific bleeding phenotype for each proband) "Most of the patients had gross blood loss due to epistaxis (54%), cutaneous bleeding (58%) and menorrhagia (100% of women), while other common symptoms (oral cavity, gastrointestinal, following dental extraction or mild injuries, postpartum, or hematomas) were in general milder.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed αIIbβ3 expression to be <5%

      PlateletAggregation: Article mentions the disorder was indentified by platelet testing consisting in severely impaired aggregation in response to all physiological agonists and also TMA (See Table 4). Ristocetin-induced platelet aggregation was normal or reduced to some extent.

      CasePreviousTesting: To detect mutations in ITGA2B or ITGB3, total RNA from peripheral blood was used for cDNA synthesis for RT-PCR. Using specific oligonucleotides and conditions, they amplified and sequenced ITGA2B and ITGB3 by Sanger sequencing, and every mutation found in cDNA was confirmed on DNA samples

      Gene: ITGA2B

      Variant: NM_000419.3:c.1599del (c.1599delAT)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940316

      gnomAD: N/A

    4. GT-9

      Case9: GT-9, age, gender or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: Segregation analysis confirmed the presence of heterozygous mutations in carrier parents

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Article mentions patients presented with variable bleeding diathesis and Table 1 shows the several phenotypes that were seen among the cohort of 13 patients in this study (this article does not state a specific bleeding phenotype for each proband) "Most of the patients had gross blood loss due to epistaxis (54%), cutaneous bleeding (58%) and menorrhagia (100% of women), while other common symptoms (oral cavity, gastrointestinal, following dental extraction or mild injuries, postpartum, or hematomas) were in general milder."

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed αIIbβ3 expression to be <5%

      PlateletAggregation: Article mentions the disorder was indentified by platelet testing consisting in severely impaired aggregation in response to all physiological agonists and also TMA (See Table 4). Ristocetin-induced platelet aggregation was normal or reduced to some extent.

      CasePreviousTesting: To detect mutations in ITGA2B or ITGB3, total RNA from peripheral blood was used for cDNA synthesis for RT-PCR. Using specific oligonucleotides and conditions, they amplified and sequenced ITGA2B and ITGB3 by Sanger sequencing, and every mutation found in cDNA was confirmed on DNA samples

      Gene: ITGA2B

      Variant: NM_000419.3:c.693dup (c.692insT)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940315

      gnomAD: N/A

      PreviouslyPublished: PMID: 12083483

    5. GT-8

      Case8: GT-8, gender, age, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: Segregation analysis confirmed the presence of heterozygous mutations in carrier parents

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Article mentions patients presented with variable bleeding diathesis and Table 1 shows the several phenotypes that were seen among the cohort of 13 patients in this study (this article does not state a specific bleeding phenotype for each proband) "Most of the patients had gross blood loss due to epistaxis (54%), cutaneous bleeding (58%) and menorrhagia (100% of women), while other common symptoms (oral cavity, gastrointestinal, following dental extraction or mild injuries, postpartum, or hematomas) were in general milder."

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed αIIbβ3 expression to be < 5%

      PlateletAggregation: Article mentions the disorder was indentified by platelet testing consisting in severely impaired aggregation in response to all physiological agonists and also TMA (See Table 4). Ristocetin-induced platelet aggregation was normal or reduced to some extent.

      CasePreviousTesting: To detect mutations in ITGA2B or ITGB3, total RNA from peripheral blood was used for cDNA synthesis for RT-PCR. Using specific oligonucleotides and conditions, they amplified and sequenced ITGA2B and ITGB3 by Sanger sequencing, and every mutation found in cDNA was confirmed on DNA samples

      Gene: ITGA2B

      Variant: NM_000419.3:c.2965del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA913189248

      gnomAD: N/A

    6. GT-7

      Case7: GT-7, gender, age, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type II

      FamilyInfo: N/A

      ParentalGenotype: Segregation analysis confirmed the presence of heterozygous mutations in carrier parents

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Article mentions patients presented with variable bleeding diathesis and Table 1 shows the several phenotypes that were seen among the cohort of 13 patients in this study (this article does not state a specific bleeding phenotype for each proband) "Most of the patients had gross blood loss due to epistaxis (54%), cutaneous bleeding (58%) and menorrhagia (100% of women), while other common symptoms (oral cavity, gastrointestinal, following dental extraction or mild injuries, postpartum, or hematomas) were in general milder."

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed αIIbβ3 expression to be between 5% and 20%

      PlateletAggregation: Article mentions the disorder was indentified by platelet testing consisting in severely impaired aggregation in response to all physiological agonists and also TMA (See Table 4). Ristocetin-induced platelet aggregation was normal or reduced to some extent.

      CasePreviousTesting: To detect mutations in ITGA2B or ITGB3, total RNA from peripheral blood was used for cDNA synthesis for RT-PCR. Using specific oligonucleotides and conditions, they amplified and sequenced ITGA2B and ITGB3 by Sanger sequencing, and every mutation found in cDNA was confirmed on DNA samples

      Gene: ITGB3

      Variant: NM_000212.2:c.431T>G (p.Met144Arg)

      LegacyVariant: (p.Met118Arg)

      ClinVar: N/A

      CAiD: CA291224645

      gnomAD: N/A

    7. GT-5

      Case5: GT-5, gender, age, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: Segregation analysis confirmed the presence of heterozygous mutations in carrier parents

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Article mentions patients presented with variable bleeding diathesis and Table 1 shows the several phenotypes that were seen among the cohort of 13 patients in this study (this article does not state a specific bleeding phenotype for each proband) "Most of the patients had gross blood loss due to epistaxis (54%), cutaneous bleeding (58%) and menorrhagia (100% of women), while other common symptoms (oral cavity, gastrointestinal, following dental extraction or mild injuries, postpartum, or hematomas) were in general milder."

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed αIIbβ3 expression to be <5%

      PlateletAggregation: Article mentions the disorder was indentified by platelet testing consisting in severely impaired aggregation in response to all physiological agonists and also TMA (See Table 4). Ristocetin-induced platelet aggregation was normal or reduced to some extent.

      CasePreviousTesting: Article mentions patients presented with variable bleeding diathesis and Table 1 shows the several phenotypes that were seen among the cohort of 13 patients in this study (this article does not state a specific bleeding phenotype for each proband) "Most of the patients had gross blood loss due to epistaxis (54%), cutaneous bleeding (58%) and menorrhagia (100% of women), while other common symptoms (oral cavity, gastrointestinal, following dental extraction or mild injuries, postpartum, or hematomas) were in general milder."

      Gene: ITGA2B

      Variant: NM_000419.3:c.1612G>T (Glu538Ter) and NM_000419.3:c.2637del c.2637delC

      LegacyVariant: (p.Glu507Ter)

      ClinVar: N/A

      CAiD: CA399802424 and CA915940297

      gnomAD: N/A

    8. GT-4

      Case4: GT-4, gender, age, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: Segregation analysis confirmed the presence of heterozygous mutations in carrier parents

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Article mentions patients presented with variable bleeding diathesis and Table 1 shows the several phenotypes that were seen among the cohort of 13 patients in this study (this article does not state a specific bleeding phenotype for each proband) "Most of the patients had gross blood loss due to epistaxis (54%), cutaneous bleeding (58%) and menorrhagia (100% of women), while other common symptoms (oral cavity, gastrointestinal, following dental extraction or mild injuries, postpartum, or hematomas) were in general milder."

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed αIIbβ3 expression to be <5%

      PlateletAggregation: Article mentions the disorder was indentified by platelet testing consisting in severely impaired aggregation in response to all physiological agonists and also TMA (See Table 4). Ristocetin-induced platelet aggregation was normal or reduced to some extent.

      CasePreviousTesting: To detect mutations in ITGA2B or ITGB3, total RNA from peripheral blood was used for cDNA synthesis for RT-PCR. Using specific oligonucleotides and conditions, they amplified and sequenced ITGA2B and ITGB3 by Sanger sequencing, and every mutation found in cDNA was confirmed on DNA samples

      Gene: ITGB3

      Variant: M_000212.2:c.647A>G (p.Tyr216Cys)

      LegacyVariant: (p.Tyr190Cys)

      ClinVar: N/A

      CAiD: CA400023432

      gnomAD: N/A

    9. GT-3

      Case3: GT-3, gender, age, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type II

      FamilyInfo: N/A

      ParentalGenotype: Segregation analysis confirmed the presence of heterozygous mutations in carrier parents

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Article mentions patients presented with variable bleeding diathesis and Table 1 shows the several phenotypes that were seen among the cohort of 13 patients in this study (this article does not state a specific bleeding phenotype for each proband) "Most of the patients had gross blood loss due to epistaxis (54%), cutaneous bleeding (58%) and menorrhagia (100% of women), while other common symptoms (oral cavity, gastrointestinal, following dental extraction or mild injuries, postpartum, or hematomas) were in general milder."

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed αIIbβ3 expression between 5% and 20%

      PlateletAggregation: Article mentions the disorder was indentified by platelet testing consisting in severely impaired aggregation in response to all physiological agonists and also TMA (See Table 4). Ristocetin-induced platelet aggregation was normal or reduced to some extent.

      CasePreviousTesting: To detect mutations in ITGA2B or ITGB3, total RNA from peripheral blood was used for cDNA synthesis for RT-PCR. Using specific oligonucleotides and conditions, they amplified and sequenced ITGA2B and ITGB3 by Sanger sequencing, and every mutation found in cDNA was confirmed on DNA samples

      Gene: ITGA2B

      Variant: NM_000419.3:c.2113T>C (p.Cys705Arg)

      LegacyVariant: (p.Cys674Arg) +31=705

      ClinVar: N/A

      CAiD: CA8602816

      gnomAD: MAF in European (non-Finnish) population is 0.000008792 http://gnomad.broadinstitute.org/variant/17-42455140-A-G

      PreviouslyPublished PMID: 9920835

    10. GT-2

      Case2: GT-2, gender, age, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: Segregation analysis confirmed the presence of heterozygous mutations in carrier parents

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Article mentions patients presented with variable bleeding diathesis and Table 1 shows the several phenotypes that were seen among the cohort of 13 patients in this study (this article does not state a specific bleeding phenotype for each proband) "Most of the patients had gross blood loss due to epistaxis (54%), cutaneous bleeding (58%) and menorrhagia (100% of women), while other common symptoms (oral cavity, gastrointestinal, following dental extraction or mild injuries, postpartum, or hematomas) were in general milder."

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% αIIbβ3 expression

      PlateletAggregation: Article mentions the disorder was indentified by platelet testing consisting in severely impaired aggregation in response to all physiological agonists and also TMA (See Table 4). Ristocetin-induced platelet aggregation was normal or reduced to some extent.

      CasePreviousTesting: To detect mutations in ITGA2B or ITGB3, total RNA from peripheral blood was used for cDNA synthesis for RT-PCR. Using specific oligonucleotides and conditions, they amplified and sequenced ITGA2B and ITGB3 by Sanger sequencing, and every mutation found in cDNA was confirmed on DNA samples

      Gene: ITGA2B

      Variant: NM_000419.3:c.641T>C (p.Leu214Pro) and NM_000419.3:c.2473_2481delinsTCACCTGGTC c.2473_2481delinsTCACCTGGTC

      LegacyVariant: (p.Leu183Pro) + 31= 214

      ClinVar: 2901

      CAiD: CA115848 and CA915940289

      gnomAD: N/A

      PreviouslyPublished PMID: 9473221 (p.Leu214Pro)

    11. GT-1

      Case1: GT-1, gender, age, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type II

      FamilyInfo: N/A

      ParentalGenotype: Segregation analysis confirmed the presence of heterozygous mutations in carrier parents

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Article mentions patients presented with variable bleeding diathesis and Table 1 shows the several phenotypes that were seen among the cohort of 13 patients in this study (this article does not state a specific bleeding phenotype for each proband) "Most of the patients had gross blood loss due to epistaxis (54%), cutaneous bleeding (58%) and menorrhagia (100% of women), while other common symptoms (oral cavity, gastrointestinal, following dental extraction or mild injuries, postpartum, or hematomas) were in general milder."

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry revealed αIIbβ3 expression between 5% and 20%

      PlateletAggregation: Article mentions the disorder was indentified by platelet testing consisting in severely impaired aggregation in response to all physiological agonists and also TMA (See Table 4). Ristocetin-induced platelet aggregation was normal or reduced to some extent.

      CasePreviousTesting: To detect mutations in ITGA2B or ITGB3, total RNA from peripheral blood was used for cDNA synthesis for RT-PCR. Using specific oligonucleotides and conditions, they amplified and sequenced ITGA2B and ITGB3 by Sanger sequencing, and every mutation found in cDNA was confirmed on DNA samples

      Gene: ITGB3

      Variant: NM_000212.2:c.448A>G (p.Met150Val) and NM_000212.2:c.774_775del (p.Cys258Ter)

      LegacyVariant: (p.Met124Val)

      ClinVar: N/A

      CAiD: CA8622961 and CA915940285

      gnomAD: MAF in South Asian population is 0.00003266 http://gnomad.broadinstitute.org/variant/17-45361895-A-G

      PreviouslyPublished PMID: 15583747 (p.Met124Val)

    12. Table 3 Molecular Diagnosis of Patients with Glanzmann Thrombasthenia:

      Case1: GT-1, age, gender, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type II

      FamilyInfo: Segregation analysis confirmed in presence of heterozygous mutations in this proband.

      ParentalGenotype: Although segregation analysis confirmed, we do not know which variant in particular came from mom or dad.

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients presented with a variable bleeding diathesis; most patients had epistaxis (54%), cutaneous bleeding (58%), and menorrhagia (100% of women) while other common symptoms (oral cavity, GI, following dental extraction of mild injuries, postpartum, or hematomas) were in general milder. There is no specific phenotypes attached to probands in this paper.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed that αIIbβ3 expression was between 5% and 20%

      PlateletAggregation: There was severely impaired aggregation in response to all physiological agonists, and ristocetin induced platelet agglutination was normal or reduced to some extent.

      CasePreviousTesting: Total RNA from peripheral blood was used for cDNA synthesis for RT-PCR. Then, using specific oligonucleotides and conditions, they amplified and sequenced ITGA2B and ITGB3 by Sanger sequencing. Every mutation found in cDNA was confirmed in DNA samples.

      Gene: ITGB3

      Variant: NM_000212.2:c.448A>G (p.Met124Val) and NM_000212.2:c.774_775del (p.Cys258Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8622961 and CA915940285

      gnomAD: MAF in South Asian population is 0.00003266 http://gnomad.broadinstitute.org/variant/17-45361895-A-G

    1. F10

      PatientID: I.1

      KindredID: F10

      Case: M, Age Unknown, Ethnicity Unknown

      DiseaseAssertion: Asymptomatic

      FamilyInfo: This patient’s partner and two children were all carriers of the D143= (c.429C>T) germline VHL variant. Their son was diagnosed with splenomegaly and polycythemia and was homozygous for the variant. All other family members were asymptomatic.

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      PreviouslyPublished: N/A

      SupplementalData: N/A

      Variant: p.D143= (c.429C>T)

      LegacyVariant: N/A

      CaseProblemVariantFreeText: N/A

      ClinVarID: 416990, https://www.ncbi.nlm.nih.gov/clinvar/variation/416990/

      CAID: N/A

      gnomAD: 0.000007953, https://gnomad.broadinstitute.org/variant/3-10188286-C-T?dataset=gnomad_r2_1

      VariantEvidence: N/A

      MutationType: missense_variant;transition; synonymous_variant

      CivicName: D143= (c.429C>T)

      MultipleGeneVariants: N/A

    1. An integrated multiomic approach as an excellent tool for the diagnosis of metabolic diseases: our first 3720 patients

      PMID:35614200

      Gene: IDUA

      Disease: MPS1

      Inheritance: Autosomal recessive

      A list of 11 IDUA variants identified in cases with MPS is included in Supplemental Table 6, but the variants are not linked to specific patients and are listed individually (not as genotypes). A page note has been added for each variant.

    1. homozygous c.2311A>G

      Gene:VWF

      HGNCID:12726

      Case:11 yo female

      DiseaseAssertion: Type 2N

      FamilyInfo:Fig. 1, family 1, patient 4

      ParentalGenotype(s):Unknown, obligate carriers

      CasePresentingHPOs:HP:0000421, HP:0012147 HP:0030132, HP:0030130

      CaseHPOFreeRext:Oral cavity and joint bleeding, Bleeding from small wounds and after tooth extraction, VWF:Ag 0.07 U/mL, VWF:Ac 0.08 U/mL, VWF:CB <0.05 U/mL, FVIII 0.01 U/mL, No VWF Multimers

      GenotypingMethod: NGS

      Gene:VWF

      Variant:c.2311A>G

      HGVS:NM_000552.5(VWF):c.2311A>G

      ClinVarID:1065273

      CAID:CA383522481

    2. homozygous c.2311A>G

      Gene:VWF

      HGNCID:12726

      Case:29 yo female

      DiseaseAssertion: Type 2N

      FamilyInfo:Fig. 1, family 1, patient 1

      ParentalGenotype(s):Unknown, obligate carriers

      CasePresentingHPOs:HP:0000421, HP:0000132, HP:0012147 HP:0030132, HP:0030130

      CaseHPOFreeRext:Skin, GI, muscle, oral cavity, and joint bleeding, VWF: Ag 0.07 U/mL, VWF:Ac 0.08 U/mL, VWF:CB 0.05 U/mL, FVIII 0.02 U/mL, No VWF Multimers

      GenotypingMethod: NGS

      Gene:VWF

      Variant:c.2311A>G

      HGVS:NM_000552.5(VWF):c.2311A>G

      ClinVarID:1065273

      CAID:CA383522481

    1. heterozygous small deletion (p.Leu 757ValfsX22) together with a large deletion of exons 48–52

      Case: IP-4

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag 3%

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: Direct sequencing of exons 2–52 including exon/intron boundaries of the VWF gene

      GenotypingMethod: multiple ligation‐dependent probe amplification (MLPA; using kit P011 and P012; MRC Holland, Amsterdam, the Netherlands) according to the manufacturer’s instructions. The PCR products were run on an ABI PRISM 3130XL sequencer with the GeneScan 500 LIZ size standard and analyzed using GeneMapper Software 5.0 (Applied Biosystems, Darmstadt, Germany). Dosage analysis based on a comparison between deleted and reference wild‐type DNA samples was performed using the Excel‐based software Coffalyser V9.4 (MRC Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: p.Leu757ValfsX22

      HGVS:

      ClinVarID:

      CAID:

      gnomAD:

      MultipleGeneVariants:

      GeneName: VWF

      Variant: deletion of exons 48-52

      ClinVarID or CAID:

      gnomAD:

    2. homozygous large deletion of exon 6

      Case: IP-1

      DiseaseAssertion: VWD3

      FamilyInfo: 6 additional family members, 5 heterozygous and 1 homozygous. All meet criteria of mild VWD1.

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF antigen (VWF:Ag) of <1%, VWF ristocetin‐cofactor activity (VWF:RCo) of <6% and factor VIII activity (FVIII:C) of 5%

      CaseNOTHPOs: NA

      CaseNOTHPOFreeText: NA

      CasePreviousTesting: Direct sequencing of exons 2–52 including exon/intron boundaries of the VWF gene

      GenotypingMethod: multiple ligation‐dependent probe amplification (MLPA; using kit P011 and P012; MRC Holland, Amsterdam, the Netherlands) according to the manufacturer’s instructions. The PCR products were run on an ABI PRISM 3130XL sequencer with the GeneScan 500 LIZ size standard and analyzed using GeneMapper Software 5.0 (Applied Biosystems, Darmstadt, Germany). Dosage analysis based on a comparison between deleted and reference wild‐type DNA samples was performed using the Excel‐based software Coffalyser V9.4 (MRC Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: deletion of exon 6

      HGVS:

      ClinVarID:

      CAID:

      gnomAD:

    3. a missense mutation (p.Arg924Gln) was combined with a large deletion spanning exons 1–5

      Case: IP-3

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0000421, HP:0000132

      CaseHPOFreeRext: VWF:Ag 1%, VWF:RCo 5% and FVIII:C 1,4%. Repetitive epistaxis, cutaneous and muscles hematomas, postpartum bleedings and a heavy menorrhagia.

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: Direct sequencing of exons 2–52 including exon/intron boundaries of the VWF gene

      GenotypingMethod: multiple ligation‐dependent probe amplification (MLPA; using kit P011 and P012; MRC Holland, Amsterdam, the Netherlands) according to the manufacturer’s instructions. The PCR products were run on an ABI PRISM 3130XL sequencer with the GeneScan 500 LIZ size standard and analyzed using GeneMapper Software 5.0 (Applied Biosystems, Darmstadt, Germany). Dosage analysis based on a comparison between deleted and reference wild‐type DNA samples was performed using the Excel‐based software Coffalyser V9.4 (MRC Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: deletion of exons 1-5

      HGVS:

      ClinVarID:

      CAID:

      gnomAD:

      MultipleGeneVariants:

      Gene: VWF

      Variant: p.Arg924Gln

      HGVS: NM_000552.5:c.2771G>A (p.Arg924Gln)

      ClinVarID: 100240

      CAID: CA228368

      gnomAD: MAF of 0.02225 (26260/118006 alleles) in Eurpoean (non-Finnish)

      https://gnomad.broadinstitute.org/variant/12-6031493-C-T?dataset=gnomad_r4

    4. homozygous small deletion in exon 45 (p.Gln2551AlafsX16)

      Case: IP-2

      DiseaseAssertion: VWD3

      FamilyInfo: The mother reported no history of bleeding episodes and the laboratory data were in the border line of the normal range.

      ParentalGenotype(s): mother is heterozygous for the p.Gln2551AlafsX16 in the VWF gene

      CasePresentingHPOs: HP:0000421

      CaseHPOFreeRext: VWF:Ag <6%, VWF:RCo <6% and FVIII:C 2%. Clinically, repetitive severe epistaxis and subcutaneous hematomas were observed.

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: Direct sequencing of exons 2–52 including exon/intron boundaries of the VWF gene

      GenotypingMethod: multiple ligation‐dependent probe amplification (MLPA; using kit P011 and P012; MRC Holland, Amsterdam, the Netherlands) according to the manufacturer’s instructions. The PCR products were run on an ABI PRISM 3130XL sequencer with the GeneScan 500 LIZ size standard and analyzed using GeneMapper Software 5.0 (Applied Biosystems, Darmstadt, Germany).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: p.Gln2551AlafsX16

      HGVS:

      ClinVarID:

      CAID:

      gnomAD:

      MultipleGeneVariants:

      GeneName: VWF

      Variant: whole gene deletion

      ClinVarID or CAID:

      gnomAD:

    1. Case: P9, Chinese, male, 11yo

      DiseaseAssertion: VWD1

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 2; VWF:Ag (%) = 5.3, VWF:RCo (%) = 4.7, FVIII:C (%) = 10.7, VWF:CB (%) = 4.5, VWFpp (%) = 4.1, VWF:RCo/VWF:Ag = 0.9, VWF:CB/VWF:Ag = 0.9, VWFpp/VWF:Ag = 0.8, FVIII:C/VWF:Ag = 2.0, RIPA (1.2 mg/ml, %) = 51.0

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.4414G>C (p.Asp1472His)

      HGVS: NM_000552.4(VWF):c.4414G>C (p.Asp1472His)

      ClinVarID: 256679; https://www.ncbi.nlm.nih.gov/clinvar/variation/256679/

      CAID: NA

      gnomAD: MAF = 0.5077 (12039/23712 alleles; 3078 homozygotes) in the African/African-American population; https://gnomad.broadinstitute.org/variant/12-6128170-C-G?dataset=gnomad_r2_1

      Variant 2: c.8079C>A (p.Cys2693Ter)

      HGVS: NM_000552.5:c.8079C>A (p.Cys2693Ter)

      ClinVarID: NA

      CAID: CA383487414; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383487414

      gnomAD: absent

    2. Case: P78, Chinese, female, 23yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 13; VWF:Ag (%) = <0.3, VWF:RCo (%) = <0.5, FVIII:C (%) = 4.3, VWF:CB (%) = <0.5, VWFpp (%) = <0.5, VWF:RCo/VWF:Ag = NA, VWF:CB/VWF:Ag = NA, VWFpp/VWF:Ag = NA, FVIII:C/VWF:Ag = NA

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.5183_5186del - unregistered variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

    3. Case: P44, Chinese, male, 6yo

      DiseaseAssertion: VWD2A

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 6; VWF:Ag (%) = 43.6, VWF:RCo (%) = 18.3, FVIII:C (%) = 38.7, VWF:CB (%) = 16.7, VWFpp (%) = 64.8, VWF:RCo/VWF:Ag = 0.4, VWF:CB/VWF:Ag = 0.4, VWFpp/VWF:Ag = 1.5, FVIII:C/VWF:Ag = 0.9

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.1870G>A (p.Gly624Ser)

      HGVS: NM_000552.4(VWF):c.1870G>A (p.Gly624Ser)

      ClinVarID: 619737; https://www.ncbi.nlm.nih.gov/clinvar/variation/619737/

      CAID: NA

      gnomAD: MAF = 0.004886 (59/12076 alleles; 1 homozygote) in the East Asian population; https://gnomad.broadinstitute.org/variant/12-6166098-C-T?dataset=gnomad_r2_1

      Variant 2: c.4883T>C (p.Ile1628Thr)

      HGVS: NM_000552.4(VWF):c.4883T>C (p.Ile1628Thr)

      ClinVarID: 284; https://www.ncbi.nlm.nih.gov/clinvar/variation/284/

      CAID: NA

      gnomAD: absent

    4. Case: P24, Chinese, male, 6yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 13; VWF:Ag (%) = 0.9, VWF:RCo (%) = 0.7, FVIII:C (%) = 5.0, VWF:CB (%) = 0.7, VWFpp (%) = 0.9, VWF:RCo/VWF:Ag = 0.8, VWF:CB/VWF:Ag = 0.8, VWFpp/VWF:Ag = 1.0, FVIII:C/VWF:Ag = 5.6

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.478G>C (p.Gly160Arg)

      HGVS: NM_000552.5:c.478G>C (p.Gly160Arg)

      ClinVarID: NA

      CAID: CA383518174; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383518174

      gnomAD: absent

    5. Case: P59, Chinese, female, 7yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 7; VWF:Ag (%) = 1.4, VWF:RCo (%) = 1.0, FVIII:C (%) = 3.9, VWF:CB (%) = 1.3, VWFpp (%) = 1.2, VWF:RCo/VWF:Ag = 0.7, VWF:CB/VWF:Ag = 0.9, VWFpp/VWF:Ag = 0.9, FVIII:C/VWF:Ag = 2.8

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.2964C>A (p.Tyr988Ter)

      HGVS: NM_000552.5:c.2964C>A (p.Tyr988Ter)

      ClinVarID: NA

      CAID: CA383516120; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383516120

      gnomAD: absent

      Variant 2: c.6540T>G (p.Tyr2180Ter)

      HGVS: NM_000552.5:c.6540T>G (p.Tyr2180Ter)

      ClinVarID: NA

      CAID: CA383490834; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383490834

      gnomAD: absent

    6. Case: P30, Chinese, female, 16yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 21; VWF:Ag (%) = 0.5, VWF:RCo (%) = <0.5, FVIII:C (%) = 2.0, VWF:CB (%) = 0.6, VWFpp (%) = <0.5`, VWF:RCo/VWF:Ag = NA, VWF:CB/VWF:Ag = 1.2, VWFpp/VWF:Ag = NA, FVIII:C/VWF:Ag = 4.0

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: Exons 6–16 del - unregistered variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

    7. Case: P89, Chinese, female, 51yo

      DiseaseAssertion: VWD2N

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 7; VWF:Ag (%) = 125.8, VWF:RCo (%) = 119.6, FVIII:C (%) = 9.8, VWF:CB (%) = 127.8, VWFpp (%) = 109.8, VWF:RCo/VWF:Ag = 1.0, VWF:CB/VWF:Ag = 1.0, VWFpp/VWF:Ag = 0.9, FVIII:C/VWF:Ag = 0.1, VWF: FVIIIB (%) = 0.1

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.2446C>T (p.Arg816Trp)

      HGVS: NM_000552.4(VWF):c.2446C>T (p.Arg816Trp)

      ClinVarID: 295; https://www.ncbi.nlm.nih.gov/clinvar/variation/295/

      CAID: NA

      gnomAD: MAF = 0.0002541 (9/35418 alleles) in the Latino/Admixed American population; https://gnomad.broadinstitute.org/variant/12-6145654-G-A?dataset=gnomad_r2_1

    8. Case: P47, Chinese, female, 23yo

      DiseaseAssertion: VWD1

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 12; VWF:Ag (%) = 4.5, VWF:RCo (%) = 3.3, FVIII:C (%) = 36.5, VWF:CB (%) = 4.2, VWFpp (%) = 5.3, VWF:RCo/VWF:Ag = 0.7, VWF:CB/VWF:Ag = 0.9, VWFpp/VWF:Ag = 1.2, FVIII:C/VWF:Ag = 8.1, RIPA (1.2 mg/ml, %) = 55.9

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.100C>T (p.Arg34Ter)

      HGVS: NM_000552.4(VWF):c.100C>T (p.Arg34Ter)

      ClinVarID: 100171; https://www.ncbi.nlm.nih.gov/clinvar/variation/100171/

      CAID: NA

      gnomAD: MAF = 0.00002645 (3/113436 alleles) in the European (non-Finnish) population; https://gnomad.broadinstitute.org/variant/12-6230460-G-A?dataset=gnomad_r2_1

      Variant 2: c.6860G>A (p.Arg2287Gln)

      HGVS: NM_000552.3:c.6860G>A (p.Arg2287Gln)

      ClinVarID: NA

      CAID: CA6401877; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA6401877

      gnomAD: MAF = 0.005415 (108/19946 alleles) in the East Asian population; https://gnomad.broadinstitute.org/variant/12-6094770-C-T

    9. Case: P8, Chinese, male 3yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 5; VWF:Ag (%) = 2.1, VWF:RCo (%) = 1.7, FVIII:C (%) = 4.8, VWF:CB (%) = 1.5, VWFpp (%) = 2.3, VWF:RCo/VWF:Ag = 0.8, VWF:CB/VWF:Ag = 0.7, VWFpp/VWF:Ag = 1.1, FVIII:C/VWF:Ag = 2.3

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.1025_1032dup - unregistered variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

      Variant 2: c.7969C>T (p.Gln2657Ter)

      HGVS: NM_000552.5:c.7969C>T (p.Gln2657Ter)

      ClinVarID: NA

      CAID: CA383487678; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383487678

      gnomAD: NA

    10. Case: P63, Chinese, female, 23yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 15; VWF:Ag (%) = 1.2, VWF:RCo (%) = 0.5, FVIII:C (%) = 5.9, VWF:CB (%) = 0.6, VWFpp (%) = 0.5, VWF:RCo/VWF:Ag = 0.4, VWF:CB/VWF:Ag = 0.5, VWFpp/VWF:Ag = 0.4, FVIII:C/VWF:Ag = 4.9

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.817C>T (p.Arg273Trp)

      HGVS: NM_000552.4(VWF):c.817C>T (p.Arg273Trp)

      ClinVarID: 100493; https://www.ncbi.nlm.nih.gov/clinvar/variation/100493/

      CAID: NA

      gnomAD: MAF = 0.00005288 (6/113462 alleles) in the European (non-Finnish) population; https://gnomad.broadinstitute.org/variant/12-6184558-G-A?dataset=gnomad_r2_1

      Variant 2: c.5335C>T (p.Arg1779Ter)

      HGVS: NM_000552.4(VWF):c.5335C>T (p.Arg1779Ter)

      ClinVarID: 100425; https://www.ncbi.nlm.nih.gov/clinvar/variation/100425/

      CAID: NA

      gnomAD: absent

    11. Case: P41, Chinese, female, 13yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 18; VWF:Ag (%) = 1.6, VWF:RCo (%) = 1.5, FVIII:C (%) = 2.8, VWF:CB (%) = 1.7, VWFpp (%) = 1.3, VWF:RCo/VWF:Ag = 0.9, VWF:CB/VWF:Ag = 1.1, VWFpp/VWF:Ag = 0.8, FVIII:C/VWF:Ag = 1.8

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.2547-13T>A - Unregistered Variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

    12. Case: P55, Chinese, female, 24yo

      DiseaseAssertion: VWD2A

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 8; VWF:Ag (%) = 35.2, VWF:RCo (%) = 14.5, FVIII:C (%) = 57.9, VWF:CB (%) = 6.5, VWFpp (%) = 21.5, VWF:RCo/VWF:Ag = 0.4, VWF:CB/VWF:Ag = 0.2, VWFpp/VWF:Ag = 0.6, FVIII:C/VWF:Ag = 1.6

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.1099T>G (p.Cys367Gly)

      HGVS: NM_000552.5:c.1099T>G (p.Cys367Gly)

      ClinVarID: NA

      CAID: CA383505165; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383505165

      gnomAD: absent

      Variant 2: c.1450_1451delinsAG (p.His484Se) - Unregisted Variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

      Variant 3: c.2423G>A (p.Cys808Tyr)

      HGVS: NM_000552.5:c.2423G>A (p.Cys808Tyr)

      ClinVarID: NA

      CAID: CA383521928; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383521928

      gnomAD: absent

    13. Case: P76, Chinese, male, 21yo

      DiseaseAssertion: VWD1

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 3; VWF:Ag (%) = 4.7, VWF:RCo (%) = 5.4, FVIII:C (%) = 27.2, VWF:CB (%) = 5.5, VWFpp (%) = 4.3, VWF:RCo/VWF:Ag = 1.1, VWF:CB/VWF:Ag = 1.2, VWFpp/VWF:Ag = 0.9, FVIII:C/VWF:Ag = 5.8, RIPA (1.2 mg/ml, %) = 73.4

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: Exon1-exon5 del - Unregistered Variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

      Variant 2: c.7464C>T (p.Gly2488=) - reported to be a splice site variant

      HGVS: NM_000552.4(VWF):c.7464C>T (p.Gly2488=)

      ClinVarID: 619755; https://www.ncbi.nlm.nih.gov/clinvar/variation/619755/

      CAID: NA

      gnomAD: MAF = 0.000008799 (1/113644 alleles) in the European (non-Finnish) population; https://gnomad.broadinstitute.org/variant/12-6080849-G-A?dataset=gnomad_r2_1

    14. Case: P35, Chinese, female, 60yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 20; VWF:Ag (%) = 1.5, VWF:RCo (%) = 1.3, FVIII:C (%) = 3.1, VWF:CB (%) = 1.1, VWFpp (%) = 1.3, VWF:RCo/VWF:Ag = 0.9, VWF:CB/VWF:Ag = 0.7, VWFpp/VWF:Ag = 0.9, FVIII:C/VWF:Ag = 2.1

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.5870delA - unregistered variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

    15. Case: P86, Chinese, female, 20yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 14; VWF:Ag (%) = 0.5, VWF:RCo (%) = <0.5, FVIII:C (%) = 5.7, VWF:CB (%) = <0.5, VWFpp (%) = <0.5`, VWF:RCo/VWF:Ag = NA, VWF:CB/VWF:Ag = NA, VWFpp/VWF:Ag = NA, FVIII:C/VWF:Ag = 11.4

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.322A>T (p.Arg108Ter)

      HGVS: NM_000552.5:c.322A>T (p.Arg108Ter)

      ClinVarID: NA

      CAID: CA383519152; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383519152

      gnomAD: absent

      Variant: Exons 6–16 del - unregistered variant

      HGVS:

      ClinVarID:

      CAID:

      gnomAD:

    16. Case: P16, Chinese, female, 25yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 15; VWF:Ag (%) = 2.1, VWF:RCo (%) = 1.9, FVIII:C (%) = 4.3, VWF:CB (%) = 1.7, VWFpp (%) = 1.5, VWF:RCo/VWF:Ag = 0.9, VWF:CB/VWF:Ag = 0.8, VWFpp/VWF:Ag = 0.7, FVIII:C/VWF:Ag = 2.0

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.1093C>T (p.Arg365Ter)

      HGVS: NM_000552.4(VWF):c.1093C>T (p.Arg365Ter)

      ClinVarID: 100172; https://www.ncbi.nlm.nih.gov/clinvar/variation/100172/

      CAID: NA

      gnomAD: absent

      Variant 2: c.8116–2delA - Unregistered variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

    17. Case: P69, Chinese, male, 12yo

      DiseaseAssertion: VWD1

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 3; VWF:Ag (%) = 2.8, VWF:RCo (%) = 2.5, FVIII:C (%) = 10.5, VWF:CB (%) = 3.2, VWFpp (%) = 2.7, VWF:RCo/VWF:Ag = 0.9, VWF:CB/VWF:Ag = 1.1, VWFpp/VWF:Ag = 1.0, FVIII:C/VWF:Ag = 3.8, RIPA (1.2 mg/ml, %) = 49.7

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.484T>C (p.Cys162Arg)

      HGVS: NM_000552.3:c.484T>C (p.Cys162Arg)

      ClinVarID: NA

      CAID: CA383518153; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383518153

      gnomAD: absent

      Variant 2: c.7884C>G (.Pro2628=) - reported to be a splice site variant

      HGVS: NM_000552.5:c.7884C>G (.Pro2628=)

      ClinVarID: NA

      CAID: CA6401487; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA6401487

      gnomAD: MAF = 0.0002175 (4/18388 alleles) in the East Asian population; https://gnomad.broadinstitute.org/variant/12-6076655-G-C

    18. Case: P37, Chinese, male, 20yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 10; VWF:Ag (%) = 0.6, VWF:RCo (%) = 0.5, FVIII:C (%) = 5.7, VWF:CB (%) = 0.6, VWFpp (%) = 0.7, VWF:RCo/VWF:Ag = 0.8, VWF:CB/VWF:Ag = 1.0, VWFpp/VWF:Ag = 1.2, FVIII:C/VWF:Ag = 9.5

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.1025_1032dup - unregistered variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

    19. Case: P85, Chinese, female, 29yo

      DiseaseAssertion: VWD2N

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type B blood, bleeding score = 2; VWF:Ag (%) = 11.0, VWF:RCo (%) = 10.9, FVIII:C (%) = 6.5, VWF:CB (%) = 11.3, VWFpp (%) = 11.0, VWF:RCo/VWF:Ag = 1.0, VWF:CB/VWF:Ag = 1.0, VWFpp/VWF:Ag = 1.0, FVIII:C/VWF:Ag = 0.6, VWF: FVIIIB (%) = 0.0

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.855G>A (p.Trp285Ter)

      HGVS: NM_000552.5:c.855G>A (p.Trp285Ter)

      ClinVarID: NA

      CAID: CA383508140; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383508140

      gnomAD: absent

      Variant 2: c.2574C>G (p.Cys858Trp)

      HGVS: NM_000552.5:c.2574C>G (p.Cys858Trp)

      ClinVarID: NA

      CAID: CA232299278; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA232299278

      gnomAD: MAF = 0.0001002 (2/19954 alleles) in the East Asian population; https://gnomad.broadinstitute.org/variant/12-6143965-G-C

    20. Case: P82, Chinese, female, 80yo

      DiseaseAssertion: VWD2M

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type AB blood, bleeding score = 10; VWF:Ag (%) = 15.6, VWF:RCo (%) = 2.7, FVIII:C (%) = 50.8, VWF:CB (%) = 14.9, VWFpp (%) = 13.6, VWF:RCo/VWF:Ag = 0.2, VWF:CB/VWF:Ag = 1.0, VWFpp/VWF:Ag = 0.9, FVIII:C/VWF:Ag = 3.3

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.3365C>T (p.Thr1122Met)

      HGVS: NM_000552.4(VWF):c.3365C>T (p.Thr1122Met)

      ClinVarID: 453122; https://www.ncbi.nlm.nih.gov/clinvar/variation/453122/

      CAID: NA

      gnomAD: MAF = 0.003169 (63/19880 alleles) in the East Asian population; https://gnomad.broadinstitute.org/variant/12-6132811-G-A?dataset=gnomad_r2_1

      Variant 2: c.3895del

      HGVS: NM_000552.5:c.3895del

      ClinVarID: NA

      CAID: CA603482918; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA603482918

      gnomAD: MAF = 0.00009925 (1/10076 alleles) in Ashkenazi Jewish population; https://gnomad.broadinstitute.org/variant/12-6128686-CA-C

      Variant 3: c.5668G>A (p.Gly1890Arg)

      HGVS: NM_000552.4(VWF):c.5668G>A (p.Gly1890Arg)

      ClinVarID: 672096; https://www.ncbi.nlm.nih.gov/clinvar/variation/627096/

      CAID: NA

      gnomAD: MAF = 0.00006559 (1/15246 alleles) in European (non-Finnish) population; https://gnomad.broadinstitute.org/variant/12-6120957-C-T?dataset=gnomad_r2_1

      Variant 4: c.6424C>T (p.Leu2142Phe)

      HGVS: NM_000552.5(VWF):c.6424C>T (p.Leu2142Phe)

      ClinVarID: 988881; https://www.ncbi.nlm.nih.gov/clinvar/variation/988881/

      CAID: NA

      gnomAD: absent

    21. Case: P11, Chinese, male, 56yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type B blood, bleeding score = 8; VWF:Ag (%) = 1.5, VWF:RCo (%) = 1.7, FVIII:C (%) = 6.2, VWF:CB (%) = 1.4, VWFpp (%) = 1.3, VWF:RCo/VWF:Ag = 1.1, VWF:CB/VWF:Ag = 0.9, VWFpp/VWF:Ag = 0.9, FVIII:C/VWF:Ag = 4.1

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.205delT - unregistered variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

      Variant 2: c.2791G>T (p.Gly931Ter)

      HGVS: NM_000552.5:c.2791G>T (p.Gly931Ter)

      ClinVarID: NA

      CAID: CA383517649; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383517649

      gnomAD: absent

    22. Case: P79, Chinese, female, 24yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type B blood, bleeding score = 9; VWF:Ag (%) = 0.5, VWF:RCo (%) = <0.5, FVIII:C (%) = 5.7, VWF:CB (%) = <0.5, VWFpp (%) = <0.5, VWF:RCo/VWF:Ag = NA, VWF:CB/VWF:Ag = NA, VWFpp/VWF:Ag = NA, FVIII:C/VWF:Ag = 11.4

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.1093C>T (p.Arg365Ter)

      HGVS: NM_000552.4(VWF):c.1093C>T (p.Arg365Ter)

      ClinVarID: 100172; https://www.ncbi.nlm.nih.gov/clinvar/variation/100172/

      CAID: NA

      gnomAD: absent

      Variant 2: c.4975C>T (p.Arg1659Ter)

      HGVS: NM_000552.4(VWF):c.4975C>T (p.Arg1659Ter)

      ClinVarID: 297; https://www.ncbi.nlm.nih.gov/clinvar/variation/297/

      CAID: NA

      gnomAD: MAF = 0.0004007 (10/24958 alleles) in the European (Finnish) population; https://gnomad.broadinstitute.org/variant/12-6127609-G-A?dataset=gnomad_r2_1

    23. Case: P64, Chinese, female, 2yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 7; VWF:Ag (%) = 1.3, VWF:RCo (%) = 1.1, FVIII:C (%) = 4.0, VWF:CB (%) = 1.5, VWFpp (%) = 0.9, VWF:RCo/VWF:Ag = 0.8, VWF:CB/VWF:Ag = 1.2, VWFpp/VWF:Ag = 0.7, FVIII:C/VWF:Ag = 3.1

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.196C>T (p.Gln66Ter)

      HGVS: NM_000552.5:c.196C>T (p.Gln66Ter)

      ClinVarID: NA

      CAID: CA383507653; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383507653

      gnomAD: absent

      Variant 2: c.4457C>A (p.Ser1486Ter)

      HGVS: NM_000552.5:c.4457C>A (p.Ser1486Ter)

      ClinVarID: NA

      CAID: CA383501822; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383501822

      gnomAD: absent

    24. Case: P49, Chinese, male, 7yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type B blood, bleeding score = 3; VWF:Ag (%) = 1.5, VWF:RCo (%) = 1.3, FVIII:C (%) = 8.0, VWF:CB (%) = 1.6, VWFpp (%) = 1.1, VWF:RCo/VWF:Ag = 0.9, VWF:CB/VWF:Ag = 1.1, VWFpp/VWF:Ag = 0.7, FVIII:C/VWF:Ag = 5.3

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.1534-13_c.1551delinsCA - unregistered variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

      Variant 2: c.2968-14A>G

      HGVS: NM_000552.5:c.2968-14A>G

      ClinVarID: NA

      CAID: CA690485152; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA690485152

      gnomAD: absent

    25. Case: P15, Chinese, female, 52yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 15; VWF:Ag (%) = 1.5, VWF:RCo (%) = 1.6, FVIII:C (%) = 7.1, VWF:CB (%) = 1.1, VWFpp (%) = 1.2, VWF:RCo/VWF:Ag = 1.1, VWF:CB/VWF:Ag = 0.7, VWFpp/VWF:Ag = 0.8, FVIII:C/VWF:Ag = 4.7

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.813C>A (p.Tyr271Ter)

      HGVS: NM_000552.5:c.813C>A (p.Tyr271Ter)

      ClinVarID: NA

      CAID: CA383508534; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383508534

      gnomAD: absent

      Variant 2: c.893dup (p.Met299fs)

      HGVS: NM_000552.4(VWF):c.893dup (p.Met299fs)

      ClinVarID: 100511; https://www.ncbi.nlm.nih.gov/clinvar/variation/100511/

      CAID: NA

      gnomAD: absent

    26. Case: P21, Chinese, male, 14yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 13; VWF:Ag (%) = 0.5, VWF:RCo (%) = <0,5, FVIII:C (%) = 2.3, VWF:CB (%) = <0.5, VWFpp (%) = <0.5, VWF:RCo/VWF:Ag = NA, VWF:CB/VWF:Ag = NA, VWFpp/VWF:Ag = NA, FVIII:C/VWF:Ag = 0.6

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.2568G>A (p.Trp856Ter)

      HGVS: NM_000552.5:c.2568G>A (p.Trp856Ter)

      ClinVarID: NA

      CAID: CA383520212; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383520212

      gnomAD: absent

      Variant 2: c.4444_4445delinsG - unregistered variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

    27. Case: P80, Chinese, female, 1yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type B blood, bleeding score = 6; VWF:Ag (%) = 0.8, VWF:RCo (%) = 1.0, FVIII:C (%) = 3.0, VWF:CB (%) = 0.7, VWFpp (%) = 0.6, VWF:RCo/VWF:Ag = 1.3, VWF:CB/VWF:Ag = 0.9, VWFpp/VWF:Ag = 0.8, FVIII:C/VWF:Ag = 3.8

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.4725delG - Unregistered Variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

      Variant 2: c.6099C>G (p.Tyr2033Ter)

      HGVS: NM_000552.5:c.6099C>G (p.Tyr2033Ter)

      ClinVarID: NA

      CAID: CA383492399; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383492399

      gnomAD: absent

    28. Case: P57, Chinese, male, 28yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type AB blood, bleeding score = 5; VWF:Ag (%) = 33.4, VWF:RCo (%) = 3.2, FVIII:C (%) = 49.2, VWF:CB (%) = 4.8, VWFpp (%) = 67.3, VWF:RCo/VWF:Ag = 0.1, VWF:CB/VWF:Ag = 0.1, VWFpp/VWF:Ag = 2.0, FVIII:C/VWF:Ag = 1.5, RIPA (0.5 mg/ml, %) = 18.2, PLT(×109/l) = 146

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.2089G>C (p.Glu697Gln)

      HGVS: NM_000552.5:c.2089G>C (p.Glu697Gln)

      ClinVarID: NA

      CAID: CA383494704; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383494704

      gnomAD: absent

      Variant 2: c.3922C>T (p.Arg1308Cys)

      HGVS: NM_000552.4(VWF):c.3922C>T (p.Arg1308Cys)

      ClinVarID: 289; https://www.ncbi.nlm.nih.gov/clinvar/variation/289/

      CAID: NA

      gnomAD: absent

      Variant 3: c.8113G>A (p.Gly2705Arg)

      HGVS: NM_000552.4(VWF):c.8113G>A (p.Gly2705Arg)

      ClinVarID: 256702; https://www.ncbi.nlm.nih.gov/clinvar/variation/256702/

      CAID: NA

      gnomAD: MAF = 0.1254 (3839/30614 alleles; 279 homozygotes)

    29. Case: P20, Chinese, female, 15yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 12; VWF:Ag (%) = 0.7, VWF:RCo (%) = 0.6, FVIII:C (%) = 3.9, VWF:CB (%) = 0.5, VWFpp (%) = 0.6, VWF:RCo/VWF:Ag = 0.9, VWF:CB/VWF:Ag = 0.7, VWFpp/VWF:Ag = 0.9, FVIII:C/VWF:Ag = 5.6

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.2217_2220dup - Unregistered Variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

    30. Case: P88, Chinese, female, 4yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 11; VWF:Ag (%) = 0.5, VWF:RCo (%) = <0.5, FVIII:C (%) = 3.0, VWF:CB (%) = <0.5, VWFpp (%) = <0.5, VWF:RCo/VWF:Ag = NA, VWF:CB/VWF:Ag = NA, VWFpp/VWF:Ag = NA, FVIII:C/VWF:Ag = 6.0

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: 1 c.1591C>T (p.Gln531Ter)

      HGVS: NM_000552.5:c.1591C>T (p.Gln531Ter)

      ClinVarID: NA

      CAID: CA383498290; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383498290

      gnomAD: absent

      Variant 2: c.6678dupC - Unregistered Variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

    31. Case: P43, Chinese, male, 7yo

      DiseaseAssertion: VWD2N

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type B blood, bleeding score = 3; VWF:Ag (%) = 48.8, VWF:RCo (%) = 49.9, FVIII:C (%) = 6.4, VWF:CB (%) = 63.9, VWFpp (%) = 52.4, VWF:RCo/VWF:Ag = 0.9, VWF:CB/VWF:Ag = 1.3, VWFpp/VWF:Ag = 1.1, FVIII:C/VWF:Ag = 0.1, VWF: FVIIIB (%) = 0.0

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.2372C>T (p.Thr791Met)

      HGVS: NM_000552.4(VWF):c.2372C>T (p.Thr791Met)

      ClinVarID: 294; https://www.ncbi.nlm.nih.gov/clinvar/variation/294/

      CAID: NA

      gnomAD: MAF = 0.00003984 (1/25100 alleles) in European (Finnish) population; https://gnomad.broadinstitute.org/variant/12-6153527-G-A?dataset=gnomad_r2_1

      Variant 2: c.2574C>G (p.Cys858Trp)

      HGVS: NM_000552.5:c.2574C>G (p.Cys858Trp)

      ClinVarID: NA

      CAID: CA232299278; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA232299278

      gnomAD: MAF = 0.0001002 (2/19954 alleles) in the East Asian population; https://gnomad.broadinstitute.org/variant/12-6143965-G-C

    32. Case: P74, Chinese, female, 26yo

      DiseaseAssertion: VWD1

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 10; VWF:Ag (%) = 4.7, VWF:RCo (%) = 4.1, FVIII:C (%) = 31.0, VWF:CB (%) = 3.6, VWFpp (%) = 5.2, VWF:RCo/VWF:Ag = 0.9, VWF:CB/VWF:Ag = 0.8, VWFpp/VWF:Ag = 1.1, FVIII:C/VWF:Ag = 6.6, RIPA (1.2 mg/ml, %) = 93.4

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.-1+3A>C

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

      Variant 2: c.3322G>C (p.Ala1108Pro)

      HGVS: NM_000552.3:c.3322G>C (p.Ala1108Pro)

      ClinVarID: NA

      CAID: CA383512138; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383512138

      gnomAD: absent

    33. Case: P23, Chinese, female 23

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 14; VWF:Ag (%) = 1.0, VWF:RCo (%) = 0.9, FVIII:C (%) = 4.7, VWF:CB (%) = 0.8, VWFpp (%) = 0.7, VWF:RCo/VWF:Ag = 0.9, VWF:CB/VWF:Ag = 0.8, VWFpp/VWF:Ag = 0.8, FVIII:C/VWF:Ag = 5.6

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.7361C>A (p.Thr2454Asn)

      HGVS: NM_000552.5:c.7361C>A (p.Thr2454Asn)

      ClinVarID: NA

      CAID: CA6401695; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA6401695

      gnomAD: MAF = 0.0003263 (6/18390 alleles) in the East Asian population; https://gnomad.broadinstitute.org/variant/12-6085353-G-T

    34. Case: P31, Chinese, female, 21yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 15; VWF:Ag (%) = 1.0, VWF:RCo (%) = 0.7, FVIII:C (%) = 4.1, VWF:CB (%) = 0.8, VWFpp (%) = 0.8, VWF:RCo/VWF:Ag = 0.7, VWF:CB/VWF:Ag = 0.8, VWFpp/VWF:Ag = 0.8, FVIII:C/VWF:Ag = 4.1

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.953_954insG - Unregistered Variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

      Variant 2: c.4368C>G (p.Tyr1456Ter)

      HGVS: NM_000552.4(VWF):c.4368C>G (p.Tyr1456Ter)

      ClinVarID: 100350; https://www.ncbi.nlm.nih.gov/clinvar/variation/100350/

      CAID: NA

      gnomAD: absent

    35. Case: P90, Chinese, female, 30yo

      DiseaseAssertion: VWD2A

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 12; VWF:Ag (%) = 10.1, VWF:RCo (%) = 3.3, FVIII:C (%) = 10.7, VWF:CB (%) = 2.6, VWFpp (%) = 151.7, VWF:RCo/VWF:Ag = 0.3, VWF:CB/VWF:Ag = 0.3, VWFpp/VWF:Ag = 15.0, FVIII:C/VWF:Ag = 1.1

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.1730-2A>G

      HGVS: NM_000552.4(VWF):c.1730-2A>G

      ClinVarID: 100189; https://www.ncbi.nlm.nih.gov/clinvar/variation/100189/

      CAID: NA

      gnomAD: absent

      Variant 2: c.6979T>A (p.Cys2327Ser)

      HGVS: NM_000552.3:c.6979T>A (p.Cys2327Ser)

      ClinVarID: NA

      CAID: CA383492042; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383492042

      gnomAD: absent

    36. Case: P38, Chinese, female, 14yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 9; VWF:Ag (%) = 1.3, VWF:RCo (%) = 1.0, FVIII:C (%) = 4.5, VWF:CB (%) = 0.7, VWFpp (%) = 0.8, VWF:RCo/VWF:Ag = 0.8, VWF:CB/VWF:Ag = 0.5, VWFpp/VWF:Ag = 0.6, FVIII:C/VWF:Ag = 3.5

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.2684A>G (p.Gln895Arg)

      HGVS: NM_000552.5:c.2684A>G (p.Gln895Arg)

      ClinVarID: NA

      CAID: CA383519914; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383519914

      gnomAD: NA

      Variant 2: c.3043G>T (p.Glu1015Ter)

      HGVS: NM_000552.5:c.3043G>T (p.Glu1015Ter)

      ClinVarID: NA

      CAID: CA383514739; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383514739

      gnomAD: absent

    1. Case: Case 2, male, newborn

      DiseaseAssertion: VWD2B

      FamilyInfo: First child of consanguineous parents (first cousins), no family history of bleeding, search of maternal platelet autoantibodies was negative; parents had VWF measurements showed decreased VWF:RCo, ratio FVIII:C/VWF:Ag < 0.5, and enhanced RIPA

      ParentalGenotype(s): both parents heterozygous for both variants

      CasePresentingHPOs: HP:0012330, HP:0001873, HP:0000967, HP:0030129

      (Pyelonephritis, thrombocytopenia, petechiae, impaired ristocetin cofactor assay activity)

      CaseHPOFreeText: born at 40wks, thrombocytopenia: 5 GL−1 at birth, platelets clumps in citrate tube, normal platelet morphology, no platelet incompatibility between the mother and the child in HPA groups 1, 3, 5, and 15, Allo- and autoantibodies on the mother and child and cross-match between father and mother serum were negative; bone marrow aspiration showed hyperplasia of megakaryocyte line, with all stages of maturation, consistent with peripheral origin, normal development; VWF:RCo = 13 IU dL−1, VWF:Ag = 47 IU dL−1, VWF:RCo /VWF:Ag= 0.3, FVIII:C = 22 IU dL−1, FVIII/VWF:Ag= 0.6, VWF:FVIII = 10 IU dL−1< RIPA analysis could not be performed

      CaseNOTHPOs: HP:0032169, HP:0001892

      (infection, abnormal bleeding)

      CaseNOTHPOFreeText: DIC

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 20 and 28 of VWF gene

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.4010C>T (p.Pro1337Leu); exon 28, homozygous

      HGVS: NM_000552.4(VWF):c.4010C>T (p.Pro1337Leu)

      ClinVarID: 100314; https://www.ncbi.nlm.nih.gov/clinvar/variation/100314/

      CAID: NA

      gnomAD: MAF = 0.00005440 (1/18384 alleles) in East Asian population; https://gnomad.broadinstitute.org/variant/12-6128574-G-A?dataset=gnomad_r2_1

      Variant 2: c.2561G>A (p.Arg854Gln); exon 20; homozygous

      HGVS: NM_000552.4(VWF):c.2561G>A (p.Arg854Gln)

      ClinVarID: 296; https://www.ncbi.nlm.nih.gov/clinvar/variation/296/

      CAID: NA

      gnomAD: MAF = 0.005692 (143/25122 alleles, 4 homozygotes) in European (non-Finnish) population; https://gnomad.broadinstitute.org/variant/12-6143978-C-T?dataset=gnomad_r2_1

    1. The older brother (hereafter called Patient A)

      Case: Patient A, male, 14 years old at WIL-29 study entry; ethnicity not reported.

      DiseaseAssertion: VWD3. The patient was initially suspected to have VWD2A based on the family history but was reclassified as VWD3 after next-generation sequencing.

      FamilyInfo: Patient A and Patient B are brothers from a consanguineous family. Both parents were diagnosed with VWD. Figure 2 shows both parents as heterozygous and Patient A and Patient B as homozygous for the familial VWF variant. The pedigree also includes another brother affected with VWD whose genetic testing was underway and a sister whose VWD diagnosis and genetic testing were pending.

      ParentalGenotype: Both parents were heterozygous for the familial VWF variant, as shown in Figure 2.

      CasePresentingHPOs: HP:0000421, HP:0030129, HP:0012147 (Epistaxis, Impaired ristocetin cofactor assay activity, Reduced quantity of VWF)

      CaseHPOFreeText: Recurrent spontaneous epistaxis. Historical VWF:RCo 1% and VWF:Ag 10%. VWF:RCo 1 IU/dL at WIL-31 screening. At the month 0 pharmacokinetic visit, pre-injection FVIII 12 IU/dL and VWF:RCo <5 IU/dL; after 60 IU/kg wilate, virtually no rise in VWF activity (maximum VWF:RCo 9 IU/dL, in vivo recovery 0.07 kg/dL). VWF inhibitors were confirmed present at WIL-31 study entry, and the patient remained inhibitor-positive at the 12-month visit.

      CaseNotHPOs: NA

      CaseNotHPOFreeText: No anaphylactic reactions or severe treatment-related adverse events were reported.

      CasePreviousTesting: Diagnosed with VWD shortly after birth and initially suspected to have VWD2A based on family history. Historical VWF activity and antigen testing, and subsequent pharmacokinetic and VWF inhibitor testing, were performed. No earlier molecular genetic testing was reported.

      GenotypingMethod: Next-generation sequencing performed in Bonn, Germany. Additional technical details regarding the sequencing assay or panel were not provided.

      Gene: VWF

      Variant: c.4094T>C p.Leu1365Pro, homozygous

      HGVS: NM_000552.5:c.4094T>C (p.Leu1365Pro)

      ClinVar: 2438545

      CAID: NA

      gnomAD: Absent (not reported in gnomAD; 0/251040 control chromosomes)

    1. Case presentation A 27-year-old woman

      Case: Proband, female, 27 years old at report; ethnicity not reported.

      DiseaseAssertion: VWD2A. The authors confirmed type 2A VWD based on VWF:Ac/VWF:Ag ratio <0.7 (excluding types 1C, 2N, and 3), RIPA negative for increased platelet affinity (excluding type 2B), and multimer analysis showing HMWM deletion with IMWM reduction (excluding type 2M).

      FamilyInfo: The patient denied a family history of abnormal bleeding. The father carried VWF c.2281+1G>A and was not diagnosed with VWD (VWF:Ag 61%, VWF:Ac 60.6%, FVIII activity 82%, VWF:Ac/VWF:Ag ratio 0.9). The mother carried VWF c.4654T>A and was diagnosed by the authors as having low VWF per British Committee for Standards in Haematology criteria (VWF:Ag 40%, VWF:Ac 26.6%, FVIII activity 66%, VWF:Ac/VWF:Ag ratio 0.6). Neither parent had a history of abnormal bleeding. Parental laboratory results and genotypes are reported in Table 2.

      ParentalGenotype: Both parents were genotyped. The father was heterozygous for c.2281+1G>A and the mother was heterozygous for c.4654T>A (Table 2). The authors report that the two variants were inherited separately from each parent, establishing compound heterozygosity. Note: Figure 2 shows Sanger sequencing validation for c.2281+1G>A only, confirming the variant in the patient and father and a normal genotype at that locus in the mother. No confirmatory sequencing trace is shown for the maternal c.4654T>A variant; that genotype is reported only in Table 2.

      CasePresentingHPOs: HP:0000421, HP:0000132, HP:0004846, HP:0012147, HP:0030132, HP:0011871 (Epistaxis, Menorrhagia, Prolonged bleeding after surgery, Reduced quantity of VWF, Absence of large von Willebrand factor multimers, Impaired RIPA)

      CaseHPOFreeText: Gingival bleeding persisted for two days after tooth extraction. History of frequent epistaxis and one episode of heavy menorrhagia in 2007 treated with plasma transfusion. ISTH-BAT bleeding score 7 (epistaxis score 1, bleeding after tooth extraction score 2, heavy menorrhagia with plasma transfusion score 4). VWF:Ag 26.2%, VWF:Ac 5.7%, FVIII activity 43%, VWF:Ac/VWF:Ag ratio 0.21. Low-concentration RIPA 23.7% (reference 30.0-70.0%). VWF multimer analysis demonstrated deletion of high-molecular-weight multimers and reduction of intermediate-molecular-weight multimers (Figure 1). Arachidonic acid-induced platelet aggregation was impaired, with a maximal aggregation rate of 14.3%.

      CaseNotHPOs: HP:0003645, HP:0001873 (Prolonged partial thromboplastin time, Thrombocytopenia)

      CaseNotHPOFreeText: APTT 39.2 s (reference 32.0-45.0), platelets 183x10^9/L (reference 125-350), PT 13.6 s (reference 11.0-15.0), and fibrinogen 2.71 g/L (reference 2.0-4.0) were all within reference ranges, as was thrombin time. High-concentration RIPA 52.9% (reference 40.0-80.0), normal. Systemic physical examination unremarkable with no active bleeding on admission. Prior laparoscopic surgery for luteal rupture without a remarkable increase in bleeding. Hemoglobin 125 g/L was marginally below the stated reference range (130-175), although the authors described the complete blood count as normal.

      CasePreviousTesting: Whole-exome sequencing was performed, which is a genome-wide method. No genes other than VWF were reported as tested or implicated. No earlier molecular genetic testing was reported.

      GenotypingMethod: Whole-exome sequencing followed by one-generation (Sanger) sequencing validation, performed on the proband and both parents.

      Variant 1

      Gene: VWF

      Variant: c.2281+1G>A, heterozygous, inherited from the father. Intron 17 canonical splice donor site; the authors describe the affected region as lying between the D2 and D' domains. Classified as pathogenic by the authors per ACMG guidelines.

      HGVS: NM_000552.5:c.2281+1G>A

      ClinVar: NA

      CAID: CA383523243

      gnomAD: Absent (gnomAD v4.1.1; variant not found, region adequately covered)

      Variant 2

      Gene: VWF

      Variant: c.4654T>A (p.Phe1552Ile), heterozygous, inherited from the mother. Exon 28, A2 domain; missense. Classified as a variant of uncertain significance by the authors per ACMG guidelines. Note: the article gives the protein consequence as p.Phe1152Ile in the Case Presentation and p.Phe1552Ile in the Discussion; these are internally inconsistent. p.Phe1552Ile is correct, as confirmed by HGVS validation and by the ClinGen Allele Registry record (NP_000543.3:p.Phe1552Ile), and is consistent with the stated exon 28 location.

      HGVS: NM_000552.5:c.4654T>A (p.Phe1552Ile)

      ClinVar: NA

      CAID: CA383500446

      gnomAD: Absent (gnomAD v4.1.1; variant not found, region adequately covered)

    1. Case#: Elayaperumal_2018_V-225 , M, 1 month (onset), origin in India

      DiseaseAssertion: VWD type 3

      FamilyInfo: consanguinity not reported, family history negative

      ParentalGenotype: not reported

      CasePresentingHPOs:

      CaseHPOFreeText: bleeding score 16, VWF:Ag 0, FVIII:C 4.1%

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: CSGE and Sanger sequencing of VWF gene only.

      Gene: VWF

      Variant: homozygous c.1117C>T (p.Arg373*)

      HGVS: NM_000552.3:c.1117C>T

      ClinVarID: 100175

      CAID: CA228261

      gnomAD: Popmax (0.00004448 ) in the south Asian population (4/30550 alleles). 0 homozygotes reported.

      MultipleGeneVariants:

    2. Case#: Elayaperumal_2018_V-270 , F, 1.5 y.o. (onset), origin in India

      DiseaseAssertion: VWD type 3

      FamilyInfo: consanguinity, no family history of bleeding

      ParentalGenotype: not reported

      CasePresentingHPOs:

      CaseHPOFreeText: bleeding score of 3, VWF:Ag of 0, FVIII:C 6.2%

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: CSGE and Sanger sequencing of VWF gene only.

      Gene: VWF

      Variant: homozygous c.3656delC (p.Pro1219Leufs*34)

      HGVS: NM_000552.3:c.3656delC

      ClinVarID: not found

      CAID:unable to register- system not processing 2/3/23

      gnomAD: not found

      MultipleGeneVariants: n/a

    3. Case#: Elayaperumal_2018_V-307 , F, 1 y.o. (onset), origin in India

      DiseaseAssertion: VWD type 3

      FamilyInfo: consanguinity reported. family history negative

      ParentalGenotype: not reported

      CasePresentingHPOs:

      CaseHPOFreeText: Bleeding score 4, VWF:Ag 0, FVIII:C 1.6%

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: CSGE and Sanger sequencing of VWF gene only.

      Gene: VWF

      Variant: homozygous c.2443-1G>C

      HGVS: NM_000552.3:c.2443-1G>C

      ClinVarID: 100222

      CAID: CA228342

      gnomAD: Popmax (-). MAF 0.000008796 (1/113692) in the European (non-Finnish) population. No homozygotes reported.

      MultipleGeneVariants:

    4. Case#: Elayaperumal_2018_V-282, F, 2 y.o. (onset), origin in India

      DiseaseAssertion: VWD type 3

      FamilyInfo: reportedly not-consanguineous. No family history of bleeding.

      ParentalGenotype: not reported

      CasePresentingHPOs:

      CaseHPOFreeText: bleeding score of 17, VWF:Ag of 0, FVIII:C 4.3%

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: CSGE and Sanger sequencing of VWF gene only.

      Gene: VWF

      Variant: heterozygous c.2683C>T (Gln895), c.3835G>A (p.Val1279Ile), c.3931C>T (p.Gln1311)

      HGVS: NM_000552.3:c.2683C>T, NM_000552.3:c.3835G>A, NM_000552.3:c.3931C>T

      ClinVarID: -,100288,100307

      CAID: -, CA228459, CA228496

      gnomAD: 1: not found 2: MAF of 0.002604 (27/10370 allele, Ashkenazi Jewish) https://gnomad.broadinstitute.org/variant/12-6128749-C-T?dataset=gnomad_r2_1 3:

      MultipleGeneVariants:

    5. Case#: Elayaperumal_2018_V-289 , F, 3 y.o. (onset), origin in India

      DiseaseAssertion: VWD type 3

      FamilyInfo: consanguinity, positive family history

      ParentalGenotype: not reported

      CasePresentingHPOs:

      CaseHPOFreeText: Bleeding score 14, VWF:Ag of 0, FVIII:C 1.7%

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: CSGE and Sanger sequencing of VWF gene only.

      Gene: VWF

      Variant: homozygous c.311_312delAG

      HGVS: NM_000552.3:c.311_312delAG (p.Gln104ArgfsTer19)

      ClinVarID: 1065296

      CAID: CA690612114

      gnomAD: not found

      MultipleGeneVariants:

    6. Case#: Elayaperumal_2018_V-294 , F, 12 y.o. (onset), origin in India

      DiseaseAssertion: VWD type 3

      FamilyInfo: no consanguinity. positive for family history (no additional details provided).

      ParentalGenotype: not reported

      CasePresentingHPOs:

      CaseHPOFreeText: VWF:Ag 0, FVIII:C 3.2%

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: CSGE and Sanger sequencing of VWF gene only.

      Gene: VWF

      Variant: homozygous c.6321G>A

      HGVS: NM_000552.3:c.6321G>A (p.Trp2107*)

      ClinVarID: not reported

      CAID: CA383491677

      gnomAD: not found

      MultipleGeneVariants: not reported

    7. Case#: Elayaperumal_2018_V-281, M, 2 y.o. (onset), origin in India

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity, no family history of bleeding

      ParentalGenotype: not reported

      CasePresentingHPOs:

      CaseHPOFreeText: bleeding score of 9, VWF:Ag of 0, FVIII:C of 3.5%

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: CSGE and Sanger sequencing of VWF gene only.

      Gene: VWF

      Variant: homozygous c.4696C>T (p.Arg1566*)

      HGVS: NM_000552.3:c.4696C>T

      ClinVarID: 100382

      CAID: CA228639

      gnomAD: MAF of 0.00001762 (2/113480 alleles, European non-Finnish) https://gnomad.broadinstitute.org/variant/12-6127888-G-A

      MultipleGeneVariants: n/a

    8. Case#: Elayaperumal_2018_V-290 , Male, 7 months (onset), origin in India

      DiseaseAssertion: VWD type 3

      FamilyInfo: no consanguinity reported. positive family history

      ParentalGenotype: not reported

      CasePresentingHPOs:

      CaseHPOFreeText: bleeding score of 12, VWF:Ag 0, FVIII:C 9.2%

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: CSGE and Sanger sequencing of VWF gene only.

      Gene: VWF

      Variant: heterozygous c.6798+1G>C

      HGVS: NM_000552.3:c.6798+1G>C

      ClinVarID: not found

      CAID: CA383489728

      gnomAD: not found

      MultipleGeneVariants:

      Note: other allele not identified. Large deletion possible.

    1. We were able to further investigate platelets and/or BOECs in one family with the Pro2808Leufs*24 variant. The pedigree and laboratory data is shown in Fig. 1. The IC, T105, is homozygous for Pro2808Leufs*24. One of her siblings heterozygous for the variant was also enrolled (T107).

      Case: IC-T105, Canadian, female

      DiseaseAssertion: VWD3

      FamilyInfo: Pedigree in Fig 1A, 4 homozygotes, 3 heterozygotes

      ParentalGenotype(s): not reported

      CasePresentingHPOs:

      CaseHPOFreeText: VWF:Ag = 0.02 IU/mL, VWF:RCo = 0.00 IU/mL, FVIII:C = 0.03, bleeding score = 18

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: sequencing of VWF gene

      PreviouslyPublished: PMID:23311757

      Gene: VWF

      Variant: c.8419_8422dup (p.Pro2808Lysfs*24) - Unregistered Variant

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

    1. 5

      Case#: 5, male, 65yo

      DiseaseAssertion: VWD1

      FamilyInfo: grandson diagnosed with VWD

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978, HP:0004846, HP:0012147, HP:0030129, HP:0030130 (Bruising susceptibility, Reduced quantity of VWF, Impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity)

      CaseHPOFreeText: Bleeding after oral surgery, ESRD awaiting renal transplantation, Type A blood, VWF:Ag (0·55–2 iu/ml) pre = 0·41, VWF:RCo (0·55–2 iu/ml) pre = 0·29, FVIII:C (0·55–2 iu/ml) pre = 0·31, FVIII:C/VWF:Ag ratio = 0·75, VWF:FVIII binding (>20%) = 12%, VWF:FVIII binding/VWF:Ag (>0·7) = 0·29, Uncomplicated kidney transplant with VWF concentrate replacement

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: RFLP; confirmatory sequencing

      Gene: VWF

      Variant 1: NM_000552.4(VWF):c.2561G>A (p.Arg854Gln)

      ClinVar: 296; https://www.ncbi.nlm.nih.gov/clinvar/variation/296/

      gnomAD: MAF = 0.005692 (European Non-Finnish); https://gnomad.broadinstitute.org/variant/12-6143978-C-T

      Variant 2: N/A - stated to be a compound heterozygote for a 2N VWD and a presumed null mutation

    2. 6

      Case#: 6, male, 20yo

      DiseaseAssertion: VWD1

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0004846, HP:0012147, HP:0030129, HP:0030130 (Epistaxis, Reduced quantity of VWF, Impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity)

      CaseHPOFreeText: posttraumatic muscle and joint bleeds, Type O blood, VWF:Ag (0·55–2 iu/ml) pre = 0·34, VWF:RCo (0·55–2 iu/ml) pre = 0·24, FVIII:C (0·55–2 iu/ml) pre = 0·24, FVIII:C/VWF:Ag ratio = 0·71, VWF:FVIII binding (>20%) = 16%, VWF:FVIII binding/VWF:Ag (>0·7) = 0·47

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: RFLP; confirmatory sequencing

      Gene: VWF

      Variant 1: NM_000552.4(VWF):c.2561G>A (p.Arg854Gln)

      ClinVar: 296; https://www.ncbi.nlm.nih.gov/clinvar/variation/296/

      gnomAD: MAF = 0.005692 (European Non-Finnish); https://gnomad.broadinstitute.org/variant/12-6143978-C-T

      Variant 2: N/A - stated to be a compound heterozygote for a 2N VWD and a presumed null mutation

    3. 2

      Case#: 2, female, 25yo

      DiseaseAssertion: VWD1

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978, HP:0000421, HP:0000132, HP:0011891, HP:0004846, HP:0012147 (bruising susceptibility, epistaxis, Menorrhagia, Post-partum hemorrhage, Reduced quantity of VWF, Impaired ristocetin cofactor assay activity)

      CaseHPOFreeText: Type A blood, VWF:Ag (0·55–2 iu/ml) pre = 0·48, VWF:RCo (0·55–2 iu/ml) pre = 0·53, FVIII:C (0·55–2 iu/ml) pre = 0·25, FVIII:C/VWF:Ag ratio = 0·52, VWF:FVIII binding (>20%) = N/A, VWF:FVIII binding/VWF:Ag (>0·7) = N/A, multiple surgical interventions with VWF concentrate with adequate haemostasis

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: RFLP; confirmatory sequencing

      Gene: VWF

      Variant 1: NM_000552.4(VWF):c.2561G>A (p.Arg854Gln)

      ClinVar: 296; https://www.ncbi.nlm.nih.gov/clinvar/variation/296/

      gnomAD: MAF = 0.005692 (European Non-Finnish); https://gnomad.broadinstitute.org/variant/12-6143978-C-T

      Variant 2: N/A - stated to be a compound heterozygote for a 2N VWD and a presumed null mutation

    1. 7

      Case#: Patient 7, Gender N/A, Onset 3-4 months. Death around 1-2 years, Southeast Asian

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: P:0001639. HP:0005165, HP:0001270, HP:0002240

      (Dyspnea, Shortened PR interval, Motor delay, Hepatomegaly

      CaseHPOFreeText: BVH, Severe MR, SDD, CK 550u/l, EF

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: Creatine Kinase enzyme 550u/l, Ejection fraction 30%, GAA enzyme activity in leukocytes was 0.05% of normal control value.

      PCR of all exons was performed and subsequently subjected to capillary Sanger sequencing in both directions

      Variant 1: NM_000152.5(GAA):c.1411_1414del (p.Glu471fs)

      ClinVar: 188874

      CAID: CA274067

      gnomAD: Highest population MAF = 0.0002513 in East Asian

      Variant 2: NM_000152.5(GAA):c.1933G>C (p.Asp645His)

      ClinVar: 189013

      CAID: CA274256

      gnomAD: Highest population MAF = 0.00005534 (East Asian)

      ParentalGenotype: Father was the carrier of variant 1 NM_000152.5(GAA):c.1411_1414del (p.Glu471fs)

      mother was carrier of variant 2 NM_000152.5(GAA):c.1933G>C (p.Asp645His)

      PreviouslyPublished: N/A

    2. 12

      Case#: Patient 12, Gender N/A, Onset at 3-4 months old, Southeast Asian

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001252, HP:0002090, HP:0002878, HP:0005165

      (Hypotonia, Pneumonia, Respiratory failure, Shortened PR interval)

      CaseHPOFreeText: Failed endotracheal extubation, BVH, mild sub-aortic obstruction, SDD, Ejection fraction 13%, creatine kinase levels 966 u/l

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: GAA enzyme activity in leukocytes was 0.10% of normal control value.

      PCR of all exons was performed and subsequently subjected to capillary Sanger sequencing in both directions

      Variant 1: c.1327-2A>G

      ClinVar: N/A

      CAID: CA401366177

      gnomAD: Highest population MAF = 0.0002297 (African)

      Variant 2: c.1437G>C (p.Lys479Asn)

      ClinVar: N/A

      CAID: CA401366671

      gnomAD: N/A

      ParentalGenotype: Mother was the carrier of variant 1 c.1327-2A>G

      Father was the carrier of variant 2 c.1437G>C (p.Lys479Asn)

      PreviouslyPublished:

    3. 1

      Case#: Patient 1, gender N/A, Age of onset was 7-8 months (died at 3 years of age), Southeast Asian

      DiseaseAssertion: Pompe Disease

      FamilyInfo:

      CasePresentingHPOs: HP:0001252, HP:0001270, HP:0001638, HP:0005165 (Muscular Hypotonia, Motor delay, Cardiomyopathy, Shortened PR interval)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: GAA activity in leukocytes was 0% of the normal control value.

      PCR of all exons was performed and subsequently subjected to capillary Sanger sequencing in both directions

      Variant1: NM_000152.5(GAA):c.876C>G (p.Tyr292Ter)

      ClinVar: 637958

      CAID: CA401363871

      gnomAD: N/A

      Variant2: NM_000152.5:c.1003G>A (p.Gly335Arg)

      ClinVar: 972790

      CAID: CA501005

      gnomAD: Highest population MAF = 0.00003266 (South Asian).

      ParentalGenotype: Patient inherited variant 1 (NM_000152.5(GAA):c.876C>G (p.Tyr292Ter) from father.

      Variant 2 (c.1003G>A (p.Gly335Arg)) was inherited from mother PreviouslyPublished:N/A

    4. 2

      Case#: Patient 2, Gender N/A, 1-2 months old at onset, Southeast Asian

      DiseaseAssertion: Pompe disease

      FamilyInfo: Patient has two previously deceased siblings with cardiomyopathy

      CasePresentingHPOs: HP:0002789, HP:0002240, HP:0005165, HP:0001639 (Tachypnea, Hepatomegaly, Shortened PR interval, Hypertrophic cardiomyopathy)

      CaseHPOFreeText: BVH, EF 30%

      CaseNotHPOs: N/A

      CaseNotHPOFreeText:N/A

      CasePreviousTesting: GAA activity in leukocytes was 0% of the normal control value

      PCR of all exons was performed and subsequently subjected to capillary Sanger sequencing in both directions

      Variant1: NM_000152.5(GAA):c.1935C>A (p.Asp645Glu)

      ClinVar: 4029

      CAID: CA116610

      gnomAD: Highes population MAF = 0.001729 (East Asian)

      Variant2: NM_000152.5(GAA):c.1933G>C (p.Asp645His)

      ClinVar:<br /> 189013

      CAID: CA274256

      gnomAD: Highest population MAF = 0.00005534 (East Asian)

      ParentalGenotype: Father was carrier of variant 1 c.1935C>A ( p.Asp645Glu

      Mother was carrier of the Variant 2 c.1933G>C (p.Asp645His

      PreviouslyPublished:

    5. 4

      Case#: Patient 4, Gender N/A, onset at 3-4 months. Died at 9 months, Southeast Asian

      DiseaseAssertion:Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0002094 HP:0001639. HP:0005165, HP:0001270 (Hypertrophic Cardiomyopathy, Dyspnea, Shortened PR interval, Motor delay )

      CaseHPOFreeText: BVH, Died from dehydration (diarrhea)

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: GAA activity in leukocytes was 0% of normal control value.

      PCR of all exons was performed and subsequently subjected to capillary Sanger sequencing in both directions

      Variant 1: c.1225dup (p.Asp409GlyfsX95)

      ClinVar: N/A

      CAID: CA923726362

      gnomAD: N/A

      Variant 2: c.2024_2026delACA (p.Asn675del)

      ClinVar: 189006

      CAID: CA274244

      gnomAD: Highest population MAF = 0.0001106 (East asians)

      ParentalGenotype: Father was carrier for Variant1 c.1226insG (p.Asp409GlyfsX95)

      Mother was carrier of Variant 2 c.2024_2026delACA (p.Asn675del)

      PreviouslyPublished: N/A

    6. 5

      Case#: Patient 5, Gender N/A, Onset at 5-6 months. Death at 1.5 years of age, Southeast Asian

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0002094 HP:0001639. HP:0005165, HP:0001270, HP:0001252, HP:0001714, HP:0002090

      (Hypertrophic Cardiomyopathy, Dyspnea, Shortened PR interval, Motor delay, Muscular hypotonia, Ventricular hypertrophy, Pneumonia )

      CaseHPOFreeText: Death from heart failure and pneumonia

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: GAA activity in leukocytes was 0% of normal control value.

      PCR of all exons was performed and subsequently subjected to capillary Sanger sequencing in both directions

      Variant 1: NM_000152.5(GAA):c.1538A>G (p.Asp513Gly)

      ClinVar: 638014

      CAID: CA401367134

      gnomAD: N/A

      ParentalGenotype: Both parents carried the .1538A>G (p.Asp513Gly) variant in the GAA gene. There was no parental consanguinity

      PreviouslyPublished: N/A

    7. 8

      Case#: Patient 8, Gender N/A, Onset at 1-2 months. Death at 13 months. Southeast Asian

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0002240, HP:0001252, HP:0002789, HP:0001698 (Hepatomegaly, Muscular hypotonia, Tachypnea, Pericardial effusion)

      CaseHPOFreeText: Hepatomegaly is mild, Pericardial effusion is mild, BHV, SDD

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: Normal PR Interval

      CasePreviousTesting: GAA activity in leukocytes was 1.46% of normal control value.

      PCR of all exons was performed and subsequently subjected to capillary Sanger sequencing in both directions

      Variant: NM_000152.5(GAA):c.877G>A (p.Gly293Arg)

      ClinVar: 4036

      CAID: CA116622

      gnomAD: Highest population MAF = 0.00005704 (Latino)

      ParentalGenotype: Both parents were carriers of the variant c.877G>A (p.Gly293Arg)

      PreviouslyPublished: N/A

    1. 1

      Case#: 1, age 36, age 30 (report)

      DiseaseAssertion: Pompe Disease

      FamilyInfo: Family 1, no further information

      CasePresenting HPOs:HP:0002878, HP:0012378, HP:0003546, HP:0001324 (Respiratory failure, fatigue, exercise intolerance, muscle weakness)

      CaseHPOFreeText: myopathy with vacuoles, biopsy with vacuolar myopathy with PAS +

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: single gene sequencing/analysis, 48.47 NaG/AaGIA, 89.61% inhibition of GAA; NaG/AaGIA above 40 and %INH above 87 are in the affected range

      Variants:

      Variant 1:NM_000152.5(GAA):c.1941C>G (p.Cys647Trp)

      ClinVar: 550327

      Variant 2: Not reported

      ParentalGenotypes: N/A

      PreviouslyPublished: N/A

    2. 2/b

      Case#: 2/b, age 11, age 5 (report)

      DiseaseAssertion: Pompe Disease

      FamilyInfo: Family 2, no further information

      CasePresenting HPOs:HP:0002878, HP:0012378, HP:0003546, HP:0001324 (Respiratory failure, fatigue, exercise intolerance, muscle weakness)

      CaseHPOFreeText: valvular myopathy, biopsy with vacuolar myopathy with PAS +

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: single gene sequencing/analysis, 105.01 NaG/AaGIA, 90.98% inhibition of GAA; NaG/AaGIA above 40 and %INH above 87 are in the affected range

      Variants:

      Variant 1:NM_000152.5(GAA):c.377G>A (p.Trp126Ter)

      ClinVar: 932904

      Variant 2: NM_000152.5(GAA):c.1655T>C (p.Leu552Pro)

      ClinVar: 279811

      ParentalGenotypes: N/A

      PreviouslyPublished: N/A

    3. 5/a

      Case#: 5/a, age 6, age 1 (report)

      DiseaseAssertion: Pompe Disease

      FamilyInfo: Family 5, no further information

      CasePresenting HPOs: HP:0001290, HP:0001639 (hypotonia, hypertrophic cardiomyopathy)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: single gene sequencing/analysis, 94.50 NaG/AaGIA, 94.31% inhibition of GAA; NaG/AaGIA above 40 and %INH above 87 are in the affected range

      Variants:

      Variant 1:NM_000152.5(GAA):c.1832G>A (p.Gly611Asp)

      ClinVar: 371226

      Variant 2:NM_000152.5(GAA):c.1832G>A (p.Gly611Asp)

      ClinVar: 371226

      ParentalGenotypes: N/A

      PreviouslyPublished: N/A

    1. Two male patients

      Case2: Male, age not specified, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Fig 3

      ParentalGenotype: Both mutations were found to be heterozygous in all family members that includes parents

      CasePresentingHPOs:

      (Gum bleeding, ecchymosis, epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed that the surface expression of GPIIb/IIIa in patients was 0% and both parents also showed reduced expression as well.

      PlateletAggregation: Platelet aggregation in response to all the agonists except risocetin was completely absent in the patient

      CasePreviousTesting: Mutation screening by conformational sensitive gel electrophoresis was performed in all the 30 exons of ITGA2B and 15 exons of ITGB3 gene in this patient

      Gene: ITGA2B

      Variant: NM_000419.3:c.1028T>C (p.Leu343Pro) and a promoter variant g.951G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399804619

      gnomAD: N/A

    2. Two male patients

      Case1: Male, age not specified, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Fig 3

      ParentalGenotype: Both mutations were found to be heterozygous in all family members that includes parents

      CasePresentingHPOs:

      (Gum bleeding, ecchymosis, epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed that the surface expression of GPIIb/IIIa in patients was 0% and both parents also showed reduced expression as well.

      PlateletAggregation: Platelet aggregation in response to all the agonists except risocetin was completely absent in the patient

      CasePreviousTesting: Mutation screening by conformational sensitive gel electrophoresis was performed in all the 30 exons of ITGA2B and 15 exons of ITGB3 gene in this patient

      Gene: ITGA2B

      Variant: NM_000419.3:c.1028T>C (p.Leu343Pro) and a promoter variant g.951G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399804619 and need to ask about second variant--made note in google doc to ask

      gnomAD: N/A

    1. The proband was a 1-year-old Japanese girl

      Case1: Female, 1 year old, Japanese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000979, HP:0000421

      (Purpura, epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: The absence of platelet GPIIb-IIIa complexes was con-firmed by flow cytometric and immunoblotting analyses. Figure 1 shows the flow cytometric analysis of the platelets

      PlateletAggregation: Absence of platelet aggregation in response to ADP, epinephrine, and collagen but the presence of a normal response to ristocetin

      CasePreviousTesting: Genomic DNA was extracted by a standard protocol from the peripheral blood mononuclear cells of the patient and her parents. The flanking region of exon 25 of the GPIIb gene including the introns was amplified by PCR from the genomic DNA.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2449-1G>C

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399795582

      gnomAD: N/A

    1. The proband is a 6-month-old Caucasian female

      Case1: Female, 6 months old, Caucasian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo:

      ParentalGenotype: Mother: Met124Val and Father: Asp119Tyr

      CasePresentingHPOs: HP:0003010

      (Prolonged bleeding time)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Diminished platelet content of αIIbβ3 in the proband (See Figure 1A)

      PlateletAggregation: The platelets from the patient did not show aggregation upon stimulation with collagen, ADP, adrenaline, or arachidonic acid, but a response to ristocetin was observed

      CasePreviousTesting: The entire coding sequences of ITGA2B and ITGB3 were determined by PCR amplification of overlapping fragments from total RNA

      Gene: ITGB3

      Variant: NM_000212.2:c.433G>T (p.Asp119Tyr) and NM_000212.2:c.448A>G (p.Met124Val)

      LegacyVariant: N/A

      ClinVar: 13554

      CAiD: CA123226 and CA8622961

      gnomAD: MAF in the South Asian population is 0.00003266 http://gnomad.broadinstitute.org/variant/17-45361895-A-G

    2. Patient TK

      Case1: (Patient TK) Male, 5 years old, Japanese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The (p.His280Pro) mutation was inherited from his mother and the (p.Gly579Ser) mutation was inherited from his father

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients (3 in this study) had suffered from a bleeding diathesis since early childhood

      CaseNotHPOs: NA

      ProteinExpression: The surface expression of the alphaIIbbeta complex on the patients' platelets was quantitated by flow cytometry. The level of antigen expression for TK was 19.9%

      Platelet Aggregation: Absent platelet aggregation in response to ADP, collagen, and epinephrine, but normal platelet agglutination in response to ristocetin

      CasePreviousTesting: The nucleotide sequences of the aIIb and b3 coding regions were determined by direct sequencing of RT-PCR products from platelet RNA

      Gene: ITGB3

      Variant: NM_000212.2:c.917A>C (p.His206Pro) and NM_000212.2:c.1813G>A (p.Gly605Ser) (See Table 1 to see zygosity statement, "double heterozygote for both variants")

      LegacyVariant: (p.His280Pro) and (p.Gly579Ser)

      ClinVar: N/A

      CAiD: CA291224999 and CA291227621

      gnomAD MAF in the East Asian population for (p.His206Pro) is 0.00005437 https://gnomad.broadinstitute.org/variant/17-45364575-A-C and MAF in East Asian population for (p.Gly605Ser) is 0.00005437 https://gnomad.broadinstitute.org/variant/17-45376796-G-A

    1. Proband 2 was a 6-year-old girl diagnosed with recurrent hematemesis (upper gastrointestinal bleeding added up to five times) at age 2.

      Case2: 6 year old, Female, Chinese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Case1 is sister of this proband. Additional family information found in table 1.

      ParentalGenotype: Father: Heterozygous for the p.Cys549Ser variant and did not find the p.Gln254Lys variant. Mother: Did not find the p.Cys549Ser variant but she is heterozygous for the p.Gln254Lys variant.

      CasePresentingHPOs: HP:0002248

      CaseHPOFreeText: Upper gastrointestinal bleeding added up to five times at age 2.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: The expression of CD41 and CD61 was detected by platelet immunofluorescence test-flow cytometry. The expression of CD41 and CD61 of Case1 was remarkably lower than other family members (261.90 and 355.45 respectively).

      CasePreviousTesting: DNA was isolated and ITGB3 and ITGA2B gene sequences were amplified by PCR with a high fidelity Taq Polymerase.

      Gene: ITGB3

      Variant: NM_000212.2:c.1646G>C (p.Cys549Ser), and NM_000212.2:c.760C>A (p.Gln254Lys)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400030198 (p.Cys549Ser) and CA400023674 (p. Gln254Lys)

      gnomAD: MAF: 0.00005453 (p.Cys549Ser) https://gnomad.broadinstitute.org/variant/17-45369890-G-C and MAF not available for (p.Gln254Lys)

    2. Proband1 was a 5-year-old girl diagnosed with recurrent epistaxis and hematuria.

      Case1: 5 year old, Female, Chinese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Case2 is the sister of this proband, additional family information found in Table 1

      ParentalGenotype: Father: Did not find the p.Cys549Ser variant and is heterozygous for p.Leu705CysfsTer4 variant. Mother: Heterozygous for the p.Cys549Ser variant and did not find the p.Leu705CysfsTer4 variant.

      CasePresentingHPOs: HP:0004406, HP:0000790

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: The expression of CD41 and CD61 was detected by platelet immunofluorescence test-flow cytometry. The expression of CD41 and CD61 of Case1 was remarkably lower than other family members (261.90 and 355.45 respectively).

      CasePreviousTesting: DNA was isolated according to the manufacturer's instruction-- ITGA2B and ITGB3 gene sequences were amplified by PCR with a high fidelity TAQ Polymerase.

      Gene: ITGB3

      Variant: NM_000212.2:c.1646G>C (p.Cys549Ser), and NM_000212.2:c.2113del (p.Leu705CysfsTer4)

      LegacyVariant: N/A

      ClinVar: Not available for either of the two variants.

      CAiD: CA400030198 (p.Cys549Ser), CA8623443 (p.Leu705CysfsTer4)

      gnomAD: MAF: 0.00005453 (p.Cys549Ser) https://gnomad.broadinstitute.org/variant/17-45369890-G-C and MAF: 0.0001087 (p.Leu705CysfsTer4) https://gnomad.broadinstitute.org/variant/17-45380183-TC-T

    1. The patient (R.M.)

      Case1: (Patient RM), Male, 73 years old, from Southwest of France

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Other family members were his mother (M.M), his son (J.M.M), and his sister (A.M)

      ParentalGenotype: Mother is heterozygous for the mutation

      CasePresentingHPOs: HP:0000421 (Epistaxis)

      CaseHPOFreeText: Life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      ProteinExpression: Flow cytometric analysis shows a reduced aIIbb3 expression in the platelets of the proband and other family members (See Fig. 6)

      Platelet Aggregation: Absent platelet aggregation in response to ADP, collagen, arachidonic acid and thrombin receptor activated peptide. Ristocetin induced platelet agglutination was normal

      CasePreviousTesting: Screening of the aIIb and b3 genes by PCR-SSCP revealed aheterozygous mutation at position 685 in exon 5 of the b3 gene leading to a 1 96Leu to Pro substitution.

      Gene: ITGB3

      Variant: NM_000212.2:c.665T>C (p.Leu6656Pro)

      LegacyVariant: (p.Leu196Pro)

      ClinVar: N/A

      CAiD: CA291224887

      gnomAD MAF in the European (non-Finnish) population is 0.00006482 https://gnomad.broadinstitute.org/variant/17-45363676-T-C

    1. The affected female child

      Case1: Female, Indian, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Parents are heterozygous for the mutation of interest

      CasePresentingHPOs: HP:0000978 (Easy bruising)

      CaseHPOFreeText: Subsequent episodes of excessive bruising

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: Absent platelet aggregation in response to ADP, epinephrine and collagen but a normal response to ristocetin

      CasePreviousTesting: Haplotype analysis was performed using polymorphic markers on chromosome 17q12–21, which included dinucleotide repeat polymorphisms (CA)n in BRCA1 gene and locus D17S579 and (CT)n within GP IIIa intron6, and the known restriction fragment length polymorphism(RFLP) markers, Fok I (GP IIb exon 26), Taq I (GP IIIa exon 8) andSma I (GP IIIa exon 9)

      Gene: ITGB3

      Variant: IVS1-14C>A (Unregistered Variant)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: N/A

      gnomAD: N/A

    1. propositusisanAshkenaziJewishfemale

      Case: Female, Ashkenazi Jewish, 2 days old at presentation

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: consanguineous marriage, pedigree in Figure 4

      ParentalGenotype: Mother carrier of Gly273Asp. Father carrier of Gly273Asp.

      CasePresentingHPOs: HP:0100309, HP:0000978, HP:0003010, HP:0004866, HP:0008320, HP:0008148, HP:0000421, HP:0001975

      (subdural bleeding, extensive ecchymoses, prolonged cutaneous bleeding time, absent platelet aggregation in response to ADP, absent platelet aggregation in response to collagen, absent platelet aggregation in response to epinephrine, occasional epistaxis, markedly decreased number of GPIIb-IIIa heterodimers)

      CaseHPOFreeText: NA

      CaseNotHPOs: HP:0011873, HP:0011871

      (normal platelet count, normal platelet agglutination in response to ristocetin)

      CaseNotHPOFreeText: NA

      ProteinExpression: <5% of the normal amount of GPIIb-GPIIIa; measured by flow cytometry

      CasePreviousTesting: PCR amplification of genomic DNA and DNA sequence analysis of the GPIIb coding sequence only.

      Gene: ITGA2B

      Variant: NM_000419.3:c.818G>A p.(Gly273Asp)

      LegacyVariant: NA

      ClinVar: 2894

      CAID: CA115837

      gnomAD: NA

  4. watermark.silverchair.com watermark.silverchair.com
    1. Therefore, we wondered whether DTT could expose the fibrinogen binding site on platelets isolated from a patient with GTV. The all& on the platelets of this patient have an Arg + Trp mutation at position 214 of P3, and the platelets fail to aggregate or to bind fibrinogen in response to physiologic agonists despite sufficient surface expression of the complex."

      Case1: (M.S) Female, 19 years old, Caucasian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The mutation has been inherited from proband's parents who are heterozygous for the same mutation the proband has.

      CasePresentingHPOs: HP:0000978 (Bruising)

      CaseHPOFreeText: Intracerebral hematoma

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Fig 4 for flow cytometry analysis of protein expression

      PlateletAggregation: Absence of platelet aggregation in response to all agonists tested i.e. ADP, collagen, platelet activating factor acether thrombin, and arachidonic acid; however, ristocetin induced platelet aggregation was normal

      CasePreviousTesting: Sequenced patient's GPIIIa exons encompasing a highlight conserved reion of GPIIIa.

      Gene: ITGB3

      Variant: NM_000212.2:c.718C>T (p.Arg240Trp)

      LegacyVariant: (p.Arg214Trp)

      ClinVar: 13555

      CAiD: CA123228

      gnomAD: MAF in the East Asian population is 0.00005437 http://gnomad.broadinstitute.org/variant/17-45363729-C-T

      PreviouslyPublished: PMID: 1602006

    1. The propositus (L.C.; II.1) in family 2 is a 17-yearold Portuguese girl

      Case2: Female, 17 years old, Portugese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Also studied were the patient’s mother (I.2), her father (I.1), and her brother (II.2). See pedigree below in article

      ParentalGenotype: Parents were heterozygous for mutation

      CasePresentingHPOs: HP:0000967

      (Petechia)

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: <5% surface expression of aIIbb3

      PlateletAggregation: Platelet aggregation is absent with ADP, collagen, epinephrine and arachidonic acid among agonists tested but the response was normal with ristocetin

      CasePreviousTesting: We examined each of the 30 exons of the b3 gene and each of the 15 exons of the aIIb gene for migration changes in PCR-SSCP analysis

      Gene: ITGB3

      Variant:

      LegacyVariant:

      ClinVar: N/A

      CAiD:

      gnomAD: MAF in the Other population is 0.0001629 https://gnomad.broadinstitute.org/variant/17-45369648-A-AC

    1. The propositus (J.V.) is a 5‐year‐old girl

      Case1: Female, 5 years old, South East Asian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Information given on paternal grandmother

      ParentalGenotype: Article mentions that NM_000419.3:c.1946+1G>A was of maternal inheritance and NM_000419.3:c.2944G>A (Val951Met) and NM_000419.3:c.2965G>A (p.Ala958Thr) is of paternal inheritance giving triple heterozygosity

      CasePresentingHPOs: HP:0000978, HP:0000421

      (Severe bruising, epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Flow cytometry showed an ∼4% residual surface expression of αIIbβ

      PlateletAggregation: No aggregation in response to ADP, epinephrine or arachidonic acid but a small residual response to collagen

      CasePreviousTesting: Extraction of genomic DNA was done and PCR amplification of DNA fragments corresponding to each of the 30 exons in ITGA2B and 15 exons of ITGB3 and SSCP analysis were all performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.2944G>A (p.Val982Met) and NM_000419.3:c.2965G>A (p.Ala989Thr) and NM_000419.3:c.1946+1G>A

      LegacyVariant: (p.Val951Met) and (p.Ala958Thr)

      ClinVar: 381747 and 417951 and 569057

      CAiD: CA16608466 and CA8602498 and CA8602901

      gnomAD: MAF in the Europmean (non-Finnish) population is 0.00006486 https://gnomad.broadinstitute.org/variant/17-42451838-C-T and MAF in the Other population is 0.001939 https://gnomad.broadinstitute.org/variant/17-42451817-C-T and MAF in the East Asian population is 0.00007555 https://gnomad.broadinstitute.org/variant/17-42456010-C-T

    1. three cases

      Case#: 2 (16 y, male - brother of Case 1, symptom onset/pain+movement limitation 8 y, diagnosis 16y)

      DiseaseAssertion: Scheie syndrome

      FamilyInfo: Male patient born to consanguineous parents

      CasePresentingHPOs: 0034337

      CaseHPOFreeText: claw hands with flexion contractures; electroneurology showed bilateral signs of mild median nerve suffering.

      CaseNotHPOs: HP:0000280; HP:0001510; HP:0000943

      CaseNotHPOFreeText: no coarse face, growth failure, other joint involvement, evidence of dysostosis multiplex of other bones. Normal intelligence, ophthalmologic, hearing and echocardiography, brain MRI

      CaseEnzymeAssay: 0.64 (umol/g/h)

      CaseUrineGAGs:

      CaseERT: Yes, after diagnosis at 16y CaseBMT:

      Variant1:c.1189+4A>T

      Variant1ClinVarID:

      Variant1CAID: CA2586965965

      Variant2: 1189+4A>T

      Variant2ClinVarID:

      Variant2CAID: CA2586965965

      AdditionalVariants:

      ParentalGenotype:

      PreviouslyPublished

    2. 19 years)

      Case#: 3 (19 y, male - cousin of Cases 1 and 2, symptom onset/pain+movement limittion 12y, diagnosis 19y))

      DiseaseAssertion: Scheie syndrome

      FamilyInfo: Male patient born to consanguineous parents

      CasePresentingHPOs:

      CaseHPOFreeText: electroneurology showed bilateral signs of mild median nerve suffering.

      CaseNotHPOs: 0034337;HP:0001510; HP:0000943

      CaseNotHPOFreeText: no coarse face, growth failure, other joint involvement, evidence of dysostosis multiplex of other bones. Normal intelligence, ophthalmologic, hearing and echocardiography, brain MRI

      CaseEnzymeAssay: 0.57 (umol/g/h)

      CaseUrineGAGs:

      CaseERT: Yes, after diagnosis at 19y

      CaseBMT:

      Variant1:c.1189+4A>T

      Variant1ClinVarID:

      Variant1CAID: CA2586965965

      Variant2: 1189+4A>T

      Variant2ClinVarID:

      Variant2CAID: CA2586965965

      AdditionalVariants:

      ParentalGenotype:

      PreviouslyPublished

    1. infant B

      Case#: Infant B

      DiseaseAssertion: MPSI

      FamilyInfo:

      CasePresentingHPOs:

      CaseHPOFreeText:

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CaseEnzymeAssay: Newborn screening, dried blood spot, modification of method published by Chamoles et al, IDUA activity <9.03 umol/L blood*20 on initial and repeat testing.

      CaseUrineGAGs: Urinary GAG obtained as part of confirmatory testing but results are not presented.

      CaseERT:

      CaseBMT:

      Variant1: c.344 G>T (D119Y), paternal origin

      Variant1ClinVarID:

      Variant1CAID:

      Variant2: c.99 T>G (H33Q), maternal origin

      Variant2ClinVarID:

      Variant2CAID:

      AdditionalVariants:

      ParentalGenotype: c.344 G>T (paternal) / c.99 T>G (maternal)

      PreviouslyPublished No

    2. infant A

      Case#: Infant A

      DiseaseAssertion: MPSI

      FamilyInfo:

      CasePresentingHPOs:

      CaseHPOFreeText:

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CaseEnzymeAssay: Newborn screening, dried blood spot, modification of method published by Chamoles et al, IDUA activity <9.03 umol/L blood*20 on initial and repeat testing.

      CaseUrineGAGs: Urinary GAG obtained as part of confirmatory testing but results are not presented.

      CaseERT: Don't know

      CaseBMT: Don't know

      Variant1: 303G > A (R105Q), paternal origin

      Variant1ClinVarID: 2020010

      Variant1CAID: CA2801866

      Variant2: c.484 G>A (R162K), maternal origin

      Variant2ClinVarID: 550594

      Variant2CAID: CA355961605

      AdditionalVariants:

      ParentalGenotype: c.303 G>A (paternal) / c.484 G>A (maternal)

      PreviouslyPublishedNo

    1. Case: Patient D

      DiseaseAssertion: VWD2N

      FamilyInfo: Family 3

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0012147, HP:0030129, HP:0030130, HP:0011871

      CaseHPOFreeText: PTsec = 37.9, FVIII U/dL = 31.1, FVIII ratio = 0.33, VWF:Ag U/dL = 95.0, VWF:FVIIIB U/dL = 23.8, VWF:FVIIIB ratio = 0.25, VWF:CB U/dL = 101.6, VWF:RCo U/dL = 112.4, RIPA % = 73.4, PlatVWF:Ag U/dL = 87.2

      CaseNOTHPOs:

      CaseNOTHPOFreeText: n/a

      CasePreviousTesting: n/a

      GenotypingMethod: "Genetic analysis was performed on exons 17-20 of the VWF gene as previously described" (PMID: 12393698)

      PreviouslyPublished: n/a

      Gene: VWF

      Variant: c.2561G>A (p.Arg854Gln); homozygous

      HGVS: NM_000552.5(VWF):c.2561G>A (p.Arg854Gln)

      ClinVarID: 296; https://www.ncbi.nlm.nih.gov/clinvar/variation/296/?new_evidence=false

      CAID: n/a

      gnomAD: MAF (European, Finnish) = 0.005692; https://gnomad.broadinstitute.org/variant/12-6143978-C-T

    2. Case: Patient C

      DiseaseAssertion: VWD2N

      FamilyInfo: Family 2

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0012147, HP:0030129, HP:0030130, HP:0011871

      CaseHPOFreeText: PTsec = 38.0, FVIII U/dL = 37.6, FVIII ratio = 0.26, VWF:Ag U/dL = 146.2, VWF:FVIIIB U/dL = 34.0, VWF:FVIIIB ratio = 0.20, VWF:CB U/dL = 157.5, VWF:RCo U/dL = 137.4, RIPA % = 87.9, PlatVWF:Ag U/dL = 102.7

      CaseNOTHPOs:

      CaseNOTHPOFreeText: n/a

      CasePreviousTesting: n/a

      GenotypingMethod: "Genetic analysis was performed on exons 17-20 of the VWF gene as previously described" (PMID: 12393698)

      PreviouslyPublished: n/a

      Gene: VWF

      Variant: c.2561G>A (p.Arg854Gln); homozygous

      HGVS: NM_000552.5(VWF):c.2561G>A (p.Arg854Gln)

      ClinVarID: 296; https://www.ncbi.nlm.nih.gov/clinvar/variation/296/?new_evidence=false

      CAID: n/a

      gnomAD: MAF (European, Finnish) = 0.005692; https://gnomad.broadinstitute.org/variant/12-6143978-C-T

    3. Case: Patient A

      DiseaseAssertion: VWD2N

      FamilyInfo: Family 1

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0012147, HP:0030129, HP:0030130, HP:0011871

      CaseHPOFreeText: PTsec = 35.2, FVIII U/dL = 18.5, FVIII ratio = 0.29, VWF:Ag U/dL = 62.9, VWF:FVIIIB U/dL = 10.7, VWF:FVIIIB ratio = 0.17, VWF:CB U/dL = 53.3, VWF:RCo U/dL = 60.4, RIPA % = 74.7, PlatVWF:Ag U/dL = 90.4

      CaseNOTHPOs:

      CaseNOTHPOFreeText: n/a

      CasePreviousTesting: n/a

      GenotypingMethod: "Genetic analysis was performed on exons 17-20 of the VWF gene as previously described" (PMID: 12393698)

      PreviouslyPublished: n/a

      Gene: VWF

      Variant: c.2561G>A (p.Arg854Gln); homozygous

      HGVS: NM_000552.5(VWF):c.2561G>A (p.Arg854Gln)

      ClinVarID: 296; https://www.ncbi.nlm.nih.gov/clinvar/variation/296/?new_evidence=false

      CAID: n/a

      gnomAD: MAF (European, Finnish) = 0.005692; https://gnomad.broadinstitute.org/variant/12-6143978-C-T

    4. Case: Patient B

      DiseaseAssertion: VWD2N

      FamilyInfo: Family 2

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0012147, HP:0030129, HP:0030130, HP:0011871

      CaseHPOFreeText: PTsec = 37.2, FVIII U/dL = 36.7, FVIII ratio = 0.33, VWF:Ag U/dL = 109.8, VWF:FVIIIB U/dL = 25.7, VWF:FVIIIB ratio = 0.23, VWF:CB U/dL = 133.8, VWF:RCo U/dL = 94.5, RIPA % = 75.8, PlatVWF:Ag U/dL = 95.4

      CaseNOTHPOs:

      CaseNOTHPOFreeText: n/a

      CasePreviousTesting: n/a

      GenotypingMethod: "Genetic analysis was performed on exons 17-20 of the VWF gene as previously described" (PMID: 12393698)

      PreviouslyPublished: n/a

      Gene: VWF

      Variant: c.2561G>A (p.Arg854Gln); homozygous

      HGVS: NM_000552.5(VWF):c.2561G>A (p.Arg854Gln)

      ClinVarID: 296; https://www.ncbi.nlm.nih.gov/clinvar/variation/296/?new_evidence=false

      CAID: n/a

      gnomAD: MAF (European, Finnish) = 0.005692; https://gnomad.broadinstitute.org/variant/12-6143978-C-T

    1. Type 3 Von Willebrand Disease: A Case Report of a Rare Entity

      Gene: VWF

      HGNCID: 12726

      Case: 4 month old female

      DiseaseAssertion: VWD type 3

      FamilyInfo: both parents were sequenced ParentalGenotype(s): mother is VWF:c.2435delC carrier, father was negative

      CasePresentingHPOs: HP:0011889 CaseHPOFreeRext: bleeding from injection site following vaccination administration CaseNOTHPOs: CaseNOTHPOFreeText: normal PT/PTT at 4 months. prolonged PTT, normal PT and platelet count upon repeat. Factor VIII levels <1%, VWF activity <15%

      GenotypingMethod: unknown

      Gene: VWF

      Variant: c.2435delC in VWF gene, deletion in exon 6 of VWF gene

      HGVS: NM_000552.5:c.2435del

      ClinVarID: 303

      gnomAD: 0.00007187 (116/1613916) https://gnomad.broadinstitute.org/variant/12-6044297-CG-C?dataset=gnomad_r4

    1. The proband

      Case: Patient UK1-IV:1, female, 31yo, Caucasian, Irish ancestry

      CasePresentingHPOs: HP:0040083, HP:0002650, HP:0001508, HP:0011471, HP:0002093, HP:0002877, HP:0001620 (toe-walking, scoliosis, poor weight gain, Feeding problem necessitating gastrostomy tube feeding, respiratory impairment, nocturnal hypoventilation, high-pitched voice)

      HPOsFreeText: scoliosis required spinal fusion surgery, required nocturnal BiPAP ventilation in adolescence, reduced muscle bulk

      Muscle biopsy showed variability in myofiber size, uniformity of type I myofibers on ATPase, moth-eaten appearance of myofibers

      CaseNotHPOs:

      FamilyInfo: non-consanguineous family

      CasePreviousTesting: 32 Illumina genes

      CaseGenotypingMethod: NGS (Illumina gene panel) or 32 genes previously associated with congenital myopathies, Sanger sequencing to confirm recessive inheritance

      InheritancePattern: autosomal recessive

      DiseaseEntity:

      Variant 1: NM_000257.3:c.4699C>T (p.Gln1657Ter), maternal

      CAID: CA389037829, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA389037829

      gnomAD: n/a

      Variant 2: NM_000257.4(MYH7):c.4664A>G (p.Glu1555Gly), paternal

      ClinVar: 181261, https://www.ncbi.nlm.nih.gov/clinvar/variation/181261/

      gnomAD: n/a

    2. Patient AUS1 IV:1

      Case: Patient AUS1-IV:1, 21yo, female, Australia

      CasePresentingHPOs: HP:0030917, HP:0008947, HP:0004323, HP:0002091, HP:0002650, HP:0003306, HP:0003701, HP:0003691, HP:0005991, HP:0002058, HP:0000268, HP:0003458 (low APGAR score, early hypotonia, abnormality of habitus, restrictive lung disease, scoliosis, spinal rigidity, proximal muscle weakness, scapular winging, limited neck flexibility, myopathic face, dolichocephaly, Myopathic electromyogram)

      HPOsFreeText: born at term, mild meconium aspiration, crawled at 10mo, walked at 18mo, thin body habitus, required nocturnal non-invasive ventilation at 13yo, required posterior spinal fusion at 3rd thoracic vertebra and 5th lumbar vertebra at 15yo, normal cardiac function, normal creatine kinase (at 13yo = 188 IU/l)

      Muscle biopsy showed variation in myofiber size with increase in internal nuclei and split myofibers, scattered nuclear bags, scattered subsarcolemmal inclusions up to 4 µm, moth-eaten and lobulated appearance of myofibers, normal phosphorylase, inclusions reactive with slow myosin resembling hyaline bodies and were shown to be composed of fine filamentous material

      CaseNotHPOs: HP:0000602, HP:0100295 (ophthalmoplegia, muscle fiber degeneration)

      FamilyInfo: Pedigree in Fig. 2, consanguineous (first-cousin) parents, Middle Eastern ancestry, no family history of neurological or cardiac abnormalities, there were 2 miscarriages prior to the proband

      CasePreviousTesting:

      CaseGenotypingMethod: Individuals IV:1 and IV:3 had NGS of 464 neurogenetic disease genes, Sanger sequencing to confirm recessive inheritance (confirmed heterozygosity in parents)

      InheritancePattern: autosomal recessive

      DiseaseEntity: n/a

      Variant: NM_000257.4(MYH7):c.5134C>T (p.Arg1712Trp), homozygous

      ClinVar: 14118, https://www.ncbi.nlm.nih.gov/clinvar/variation/14118/

      gnomAD: n/a

    1. They were the parents of a baby girl (V.4) diagnosed at 7 months of life as having isolated severe concentric hypertrophy without outflow obstruction and an ejection fraction of 70%

      Case#: V.4, female, age of diagnosis 7 months, Moroccan

      DiseaseAssertion: Pompe disease

      FamilyInfo: Pedigree (figure 2). V.4 parents are cousins (IV.2 and IV.3). V.4 had a cousin (V.3) that died at 8 months of age and was diagnosed with HCM. V.3 parents (IV.1 and IV.4) are cousins. IV.2, IV.3, IV.1 and IV.4 were all heterozygous for the GAA mutation c.236_246del (p.Pro79ArgfsX13). V.4 was homozygous for the mutation.

      CasePresentingHPOs: HP:0005157, HP:0001290

      (Concentric hypertrophy, generalized hypotonia)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: hypotonia without facial dysmorphia or other associated abnormalities.

      The heart was structurally normal and no valvular anomalies were observed.

      CasePreviousTesting: whole exome sequencing (WES), Sanger sequencing. No metabolic screening was performed.

      Molecular analysis of SMN gene excluded Spinal muscular atrophy, one of the major causes of neonatal hypotonia in Morocco.

      Variant: NM_000152.5 c.236_246del (p.Pro79ArgfsX13)

      ClinVar: 371302

      CAID: CA16041880

      gnomAD: N/A

      ParentalGenotype: Both parents are heterozygous for .236_246del (p.Pro79ArgfsX13)

      PreviouslyPublished: N/A

    1. 1

      Case1: Gender or age not specified, Thai ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Father: p.Arg584Ter/WT and Mother: p.Leu973Alafs*63/WT (See Table 2)

      Note: No parental consanguinity

      CasePresentingHPOs: N/A

      CaseHPOFreeText: The article does not mention specific bleeding phenotypes for each of the 4 probands in the article, rather, there is a general statement that says: "The common presentations included recurrent epistaxis, bleeding in oral cavity, and easy-bruising spontaneously or after trauma"

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinEpression: General statement from the article that states that flow cytometry to assess the surface GPIIb/IIIa complex showed reduced expression for all probands.

      PlateletAggregation: The platelet aggregation test was typically defective with all physiological agonists except ristocetin, for all patients.

      CasePreviousTesting: Whole exome sequencing was performed on the 30 exons of ITGA2B and 15 exons in ITGB3. PCR and direct sequencing were then performed in the DNA samples of the patients and their available parents to verify the presence of the identified mutations.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1750C>T (p.Arg584Ter) and NM_000419.3:c.2915dup (p.Leu973Alafs*63)

      LegacyVariant: N/A

      ClinVar: 2892 (p.Arg584Ter)

      CAiD: CA115834 (p.Arg584Ter) and CA8602531 (p.Leu973Alafs*63)

      gnomAD: MAF for (p.Arg584Ter) in the East Asian population 0.0002176 http://gnomad.broadinstitute.org/variant/17-42457372-G-A and MAF for (p.Leu973Alafs*63) in the East Asian population 0.0001088 http://gnomad.broadinstitute.org/variant/17-42452054-C-CG

    1. The propositus (A.C.S.; II.1) in family 1 is a 22-yearold Portuguese girl

      Case1: Female, 22 years old, Portuguese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Also studied were the probands mother (I.2) father (1.1) and sister (II.2) and only her sister has reported excessive bleeding, although her platelet aggregation tests were normal for all of them (See Fig. 2A)

      ParentalGenotype: Parents were heterozygous

      CasePresentingHPOs: HP:0000967

      (Petechia)

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Western blot expression study shows classic type 1 GT with less than 5% surface expression of aIIb3

      PlateletAggregation: Platelet aggregation was absent with physiological agonists but agglutination with ristocetin was normal

      CasePreviousTesting: Examined each of the 30 exons of beta3 gene and each of the 15 exons of the aIIb gene for migration changes in PCR-SSCP analysis. Each PCR reaction was controlled by electrophoresis of the amplified fragments on 1.5% agarose gels

      Gene: ITGB3

      Variant: NM_000212.2:c.1924G>T (p.Glu642Ter)

      LegacyVariant: N/A

      ClinVar: 13565

      CAiD: CA123249

      gnomAD: N/A

    1. Patients with the French gypsy mutation

      Note that I have clumped these patients together as there is very minimal information provided about each proband --> what is presented is just the fact that they all have the French Gypsy mutation

      Cases 19, 20, 21, 22, 23, 24, 25, 26, 27: All have Gypsy mutation and their gender and age are not specified here

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD: N/A

    1. F3P1

      Case3: Patient F3P1, Male, 26 years old, Tunisian

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: Table 1 states there is a family history of bleeding (we have minimal to no specific info on this)

      ParentalGenotype: Mother and father are heterozygous for this mutation

      CasePresentingHPOs: HP:0000225, HP:0004406, HP:0000978,HP:0000790, HP:0002239

      (Gingival bleeding, recurrent epistaxis, easy bruising, hematuria, GI bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: GT diagnosis was based on absent platelet aggregation induced by ADP, collagen, and TRAP and subnormal or cyclical ristocetin induced agglutination

      CasePreviousTesting: Using PCR they successfully amplified 20 DNA fragments for the ITGA2B gene (covering more than 48% of the ITGA2B gene constituting 30 exons) and15 DNA fragments of theITGB3gene (covering 15 exons)

      Gene: ITGA2B

      Variant: NM_000419.3:c.2702C>A (p.Ser901X) another variant this patient has is g.13944G>A --> I am noting this as Unknown Variant as I will need guidance curating this one

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399792888

      gnomAD: N/A

    1. patient 8

      Case#: Patient 8

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not provided

      ParentalGenotype: Not provided

      CasePresentingHPOs: (HP:0000421, Epistaxis)

      PlateletAggregation: All patients had abnormal platelet aggregation studies prompting analysis of platelet glycoprotein expression by flow cytometry.

      ProteinExpression: Flow cytometry, 11 of 12 patients with GT had reduced antibody binding to GPIIb/IIIa

      CasePreviousTesting: Not provided

      PreviouslyPublished: Not provided

      Gene: ITGA2B

      Variant: c.1750C>T, p. (R584X)

      HGVS: NM_000419.5:c.1750C>T

      ClinVar: 2892 https://www.ncbi.nlm.nih.gov/clinvar/variation/2892/

      CAID: CA115834

      gnomAD: PopMax = 0.00008834 https://gnomad.broadinstitute.org/variant/17-44380004-G-A?dataset=gnomad_r4

      Variant: c.2671C>T, p. (Q891X)

      HGVS: NM_000419.5:c.2671C>T

      ClinVar: 953054 https://www.ncbi.nlm.nih.gov/clinvar/variation/953054/

      CAID: CA8602626

      gnomAD: PopMax = 0.000007390 https://gnomad.broadinstitute.org/variant/17-44375647-G-A?dataset=gnomad_r4

    1. The patient was a 35‐year‐old female

      Case1: Female, 35 years old, Japanese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Pedigree found in Fig 4

      ParentalGenotype: Mother: heterozygote for (p.Ile330Asn) and Father: heterozygote for (p.His306Pro)

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Profuse bleeding at times

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: The surface expression of αIIbβ3 complex on the patient's platelets was not observed in the flow cytometric analysis used to detect the αIIbβ3 complex (Fig. 1A).

      PlateletAggregation: No aggregation of patient's platelets in response to ADP and collagen but normal aggregation occurred in response to ristocetin

      CasePreviousTesting: Nucleotide sequences of beta3 cDNA and beta3 genomic DNA were analyzed by the dye terminator cycle sequencing method, in addition the nucleotide sequences of alphaIIbeta cDNA were anlso analyzed based on the published sequence of alphaIIbeta

      Gene: ITGB3

      Variant: NM_000212.2:c.989T>A (p.Ile330Asn) and NM_000212.2:c.917A>C (p.His306Pro)

      LegacyVariant: (p.Ile304Asn) and (p.His280Pro)

      ClinVar: N/A

      CAiD: CA400025722 and CA291224999

      gnomAD: MAF in the East Asian population is 0.00005437 https://gnomad.broadinstitute.org/variant/17-45364575-A-C

  5. watermark.silverchair.com watermark.silverchair.com
    1. The patient, a 14-year-old boy

      Case1: Male, 14 years old, Tunisian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Parents were heterozygous for the variant of interest

      CasePresentingHPOs: HP:0000421, HP:0000225, HP:0031364

      (Epistaxis, gingival bleeding, ecchymosis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: The proband's platelets did not express GPIIb and small amounts of GPIIIa were detected.

      PlateletAggregation: Absence of platelet aggregation after stimulation by ADP, collagen, and thrombin. Ristocetin-induced platelet agglutination was normal

      CasePreviousTesting: Exon 26 of the GPIIb gene was amplified by PCR with primers

      Gene: ITGA2B

      Variant: NM_000419.3:c.2702C>A (p.Ser901Ter)

      LegacyVariant: (p.Ser870Ter)

      ClinVar: N/A

      CAiD: CA399792888

      gnomAD: N/A

    1. female infant

      Case#: Female, at birth

      DiseaseAssertion: Glanzmann Thrombasthenia

      FamilyInfo: Figure 1 Consanguinity Mother: 27 yo. Positive for mutation. Epistaxis, hypochromic microcytic anemia, cesarean postoperative vaginal bleeding. Maternal aunt present with GT, Positive for mutation. Maternal cousin present with GT, Positive for mutation. Paternal cousins present with GT, Positive for mutation.

      ParentalGenotype: Both parents heterozygous carriers.

      CasePresentingHPOs: HP:0000978, Bruising susceptibility. HP:0000225, Gingival bleeding. HP:0003265, Neonatal hyperbilirubinemia. HP:0011869, Abnormal platelet function. HP:0004887, Respiratory failure requiring assisted ventilation. HP:0000967, Petechiae.

      PlateletAggregation: Normal coagulation. Reduced platelet function.

      CaseHPOFreeText: APGAR score 9. Spontaneous skin bruising. Started on feeds second day of life.

      ProteinExpression: Platelet function assays showed severely reduced activity.

      Gene: ITGB3

      Variant: p.Asp145Asn

      HGVS: NP_000203.2:p.Asp145Asn

      ClinVar: 627066

      CAID: CA400021939

      gnomAD: Absent

    1. Case 2

      Case2: Male, 9 years old, Japanese

      DiseaseAssertion: Macrothrombocytopenia

      FamilyInfo: Information on mother is given (minimal other family information)

      ParentalGenotype: Mother: ITGA2B (Phe993del heterozygous)

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Surface expression of αIIbβ3 in platelets of the patient and his mother was about 80% compared to control subjects with an increase of CD42b expression

      PlateletAggregation: N/A

      CasePreviousTesting: The entire coding sequence of exons and exon-intron boundaries of ITGA2B and ITGB3 and the whole coding regions of ITGA2B and ITGB3 cDNA obtained from platelets were sequenced as previously described. In the case of ITGA2B p.Phe993del, PCR products obtained from amplification of exon 30 of ITGA2B from the patient's DNA were subcloned to pCR2.1-TOPO and sequence analysis was performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.3070_3072del (p.Phe1024del)

      LegacyVariant: p.Phe993del legacy nomenclature

      ClinVar: N/A

      CAiD: CA8602460

      gnomAD: N/A

    2. Case 3

      Case3: Female, 8 years old, Japanese

      DiseaseAssertion: Thrombocytopenia

      FamilyInfo: Information on mother and grandfather available in Table 1(minimal information on other family members)

      ParentalGenotype: Mother: ITGB3 (p.Asp621_Glu660del heterozygous) See Table 1

      CasePresentingHPOs: HP:0000978 (Bruising)

      CaseHPOFreeText: Subaponeurotic hematoma

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Surface expression levels of αIIbβ3 in platelets of patient were decreased to around 65% of normal subjects with increase of CD42b (See Table 1)

      PlateletAggregation: N/A

      CasePreviousTesting: Sequence analysis of DNA revealed the patient's mutation. RT-PCR was also performed. The entire coding sequence of exons and exon-intron boundaries of ITGA2B and ITGB3 and the whole coding regions of ITGA2B and ITGB3 cDNA obtained from platelets were sequenced.

      Gene: ITGB3

      Variant: NM_000212.2:c.2134+1G>A (p.Asp621_Glu660del)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400033344

      gnomAD: N/A

    1. Three samples were confirmed to have nucleotide changes consistent with MPS-I (Table II).

      Case#:Table II, MPS-I, Enzyme activity=1.15

      DiseaseAssertion: MPS1

      FamilyInfo:

      CasePresentingHPOs:

      CaseHPOFreeText:

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CaseEnzymeAssay: 1.15 umol/hr/L blood (newborn blood spot)

      CaseUrineGAGs:

      CaseERT:

      CaseBMT:

      Variant1:c.246C>G (p.His82Gln)

      Variant1ClinVarID: 92637

      Variant1CAID: CA220506

      Variant2: c.246C>G (p.His82Gln)

      Variant2ClinVarID: 92637

      Variant2CAID: CA220506

      AdditionalVariants:

      ParentalGenotype:

      PreviouslyPublished

    2. Three samples were confirmed to have nucleotide changes consistent with MPS-I (Table II).

      Case#:Table II, MPS-1, Enzyme activity=1.05

      DiseaseAssertion: MPS1

      FamilyInfo:

      CasePresentingHPOs:

      CaseHPOFreeText:

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CaseEnzymeAssay: 1.05 umol/hr/L blood, newborn blood spot

      CaseUrineGAGs:

      CaseERT:

      CaseBMT:

      Variant1:c.208C>T (p.Gln70X)

      Variant1ClinVarID: 11909

      Variant1CAID: CA204563

      Variant2: c.208C>T (p.Gln70X)

      Variant2ClinVarID: 11909

      Variant2CAID: CA204563

      AdditionalVariants:

      ParentalGenotype:

      PreviouslyPublished

    3. Three samples were confirmed to have nucleotide changes consistent with MPS-I (Table II).

      Case#:Table II, MPS-1, Enzyme activity=1.06*

      DiseaseAssertion: MPS1

      FamilyInfo:

      CasePresentingHPOs:

      CaseHPOFreeText:

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CaseEnzymeAssay: 1.06 umol/hr/L blood, newborn blood spot

      CaseUrineGAGs:

      CaseERT:

      CaseBMT:

      Variant1:c.355G>T (p.Asp119Tyr)

      Variant1ClinVarID: 2432701

      Variant1CAID: CA2801882

      Variant2: c.250G>A (p.Gly84Ser)

      Variant2ClinVarID: 726495

      Variant2CAID: CA2801152

      AdditionalVariants:

      ParentalGenotype:

      PreviouslyPublished

    1. V‐138

      Case#: Elayaperumal_2018_V-138, F, 2 y.o. (onset), origin in India

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity, family history of bleeding

      ParentalGenotype: not reported

      CasePresentingHPOs:

      CaseHPOFreeText: bleeding score of 19, VWF:Ag of 0, FVIII:C of 1.9%

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: CSGE and Sanger sequencing of VWF gene only.

      Gene: VWF

      Variant: Heterozygous c.3379+1G>A

      HGVS: NM_000552.3:c.3379+1G>A

      ClinVarID: 100257

      CAID: CA228398

      gnomAD: MAF 0.0001508 (3/19892 alleles, East Asian population) https://gnomad.broadinstitute.org/variant/12-6132796-C-T

      MultipleGeneVariants: Since this patient was reportedly heterozygous, they should have another variant. However, only one was reported.

    2. V‐136

      Case#: Elayaperumal_2018_ , M, 4 y.o. (onset), origin in India

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity, no family history

      ParentalGenotype: not reported

      CasePresentingHPOs:

      CaseHPOFreeText: bleeding score of 14. VWF:Ag 0.83, FVlll:C of 1.9%.

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: CSGE and Sanger sequencing of VWF gene only.

      Gene: VWF

      Variant: homozygous c.757_770del

      HGVS: NM_000552.3:c.757_770del (p.Thr253Cysfs*45)

      ClinVarID: not found

      CAID: CAR unable to parse. Error: unknown

      gnomAD: not found

      MultipleGeneVariants: not reported

    1. P20

      Case: P20, F/33

      DiseaseAssertion: VWD1

      FamilyInfo: No family history

      ParentalGenotype: NA

      CaseHPOFreeText: The bleeding score was 4, aPTT was 25 seconds, FVIII:C was 6%, VWF:RCo was 19 IU/dL, and VWF:Ag was 19 IU/dL, with a VWF:RCo/VWF:Ag ratio of 1.0. RIPA was normal, VWF multimer analysis was not tested, and platelet count was 475 × 10⁹/L.

      CasePreviousTesting: NA

      GenotypingMethod: Direct sequencing of all exons, flanking intronic sequences, and the promoter of VWF was performed.

      Gene: VWF

      Variant: c.1135T>G, p.C379G, c.7390C>T, p.R2464C. Compound heterozygous

      HGVS: NM_000552.5(VWF):c.1135T>G (p.Cys379Gly), NM_000552.5(VWF):c.7390C>T (p.Arg2464Cys)

      ClinVar: 100467

      CAID: CA6403534 , CA228786

      gnomAD: https://gnomad.broadinstitute.org/variant/chr12-6071318-A-C?dataset=gnomad_r4, https://gnomad.broadinstitute.org/variant/chr12-5976158-G-A?dataset=gnomad_r4

    1. P1

      Case: P1, female, 36yo

      DiseaseAssertion: VWD2M

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147, HP:0030129, HP:0030130

      (Reduced quantity of VWF, Impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity)

      CaseHPOFreeText: bleeding score = 7; VWF:Ag (%) = 22, VWF:RCo(%) = 11, VWF:RCo/VWF:Ag ratio = 0.50, VWF:CIIIB (%) = 19, VWF:CIIIB/VWF:Ag ratio = 0.86, VWF:CVIB (%) = 13, VWF:CVIB/VWF:Ag ratio = 0.59

      CaseNOTHPOs: HP:0030132

      (Absence of large von Willebrand factor multimers)

      CaseNOTHPOFreeText: NA

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.3944G>A (p.Arg1315His)

      HGVS: NM_000552.4(VWF):c.3944G>A (p.Arg1315His)

      ClinVarID: 100311; https://www.ncbi.nlm.nih.gov/clinvar/variation/100311/

      CAID:

      gnomAD: MAF = 0.0001633 (1/6124 alleles) in "Other" population; https://gnomad.broadinstitute.org/variant/12-6128640-C-T?dataset=gnomad_r2_1

      Variant 2: c.7464C>T (p.Gly2488=)

      HGVS: NM_000552.4(VWF):c.7464C>T (p.Gly2488=)

      ClinVar: 619755; https://www.ncbi.nlm.nih.gov/clinvar/variation/619755/

      gnomAD: MAF = 0.000008799 (1/113644 alleles) in European (Non-Finnish) population; https://gnomad.broadinstitute.org/variant/12-6080849-G-A?dataset=gnomad_r2_1

    1. type 3‐VWD patient

      Case:44‐year‐old male patient

      DiseaseAssertion:type 3‐VWD patient

      FamilyInfo:positive family hsiory: The proband and his sister both had low FVIII:C (1 IU/dL) and VWF:Ag (3 IU/dL) levels, confirming the diagnosis of type 3 VWD. His father had nearly normal levels of FVIII:C (58 IU/dL) and VWF:Ag (57 IU/dL). His daughter had type 1 VWD with decreased FVIII:C (46 IU/dL) and VWF:Ag (19 IU/dL)., NGS identified a heterozygous VWF c.2328delT (p.A778Lfs*23) frame shift mutation only in the proband and his sister

      ParentalGenotype(s):VWF missense mutation, c.6521G > T (p.C2174F), was found heterozygous in father, but mother not tested

      CasePresentingHPOs:BAT score=16, Arterial thrombosis=ischemic stroke, FVIII:C*=1, VWF:Ag=3, Proein S:58, Protein C:100, antithrombin III=106, activated protein C resistance:2.9. CaseHPOFreeRext: Complete blood count showed normocytic anemia (hemoglobin 74 g/L), normal white cell (and differential), and platelet counts. He had prolonged activated partial thromboplastin time (APTT) (89.4 s (s) [reference range (RR), 28.0–44.0 s]) with greatly decreased FVIII:C (1 IU/dL) and VWF:Ag (3 IU/dL) (Table 1). Abdominal ultrasound scanning revealed fatty liver, normal gallbladder, spleen, pancreas, and kidneys. Four hundred ml of virus inactivated fresh frozen plasma (FFP) was transfused, and his VWF:Ag increased to 6 IU/dL. On Day 2 after admission, the patient abruptly experienced numbness and weakness in his right limb.

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:n.a

      GenotypingMethod:NGS

      PreviouslyPublished: If applicable.

      Gene: VWF

      Variant:c.2328delT (p.A778Lfs*23) and c.6521G > T (p.C2174F)

      HGVS:n.a.

      ClinVarID:n.a.

      CAID:n.a.

      gnomAD: n.a.

    1. p.Gly2752Ser

      PMID:35491445

      Gene:VWF

      HGNCID:12726

      Case:49‐year‐old Japanese male

      DiseaseAssertion:type 3 VWD phenotype

      FamilyInfo: Figure A Proband II-2, Parents I-1 & I-2 are cousins, Sons III-1 & III-2

      ParentalGenotype(s): Consanguineous parents are asymptomatic and heterozygotes for VWFGly2752Ser

      CasePresentingHPOs:HP:0000421, HP:0012147, HP:0030129, HP:0030130

      CaseHPOFreeRext:VWF:Ag<5% or 0.12 ug/ml, VWF:RCo < 6%, FVIII:C 11%

      CaseNOTHPOs: HP:0001934

      GenotypingMethod:WES and Sanger sequencing

      Gene:VWF

      Variant:Homozygous c.8254 G>A(p.Gly2752Ser)

      HGVS:NM_000552.5:c.8253+39C>T NC_000012.12:g.5949747G>A <br /> NC_000012.11:g.6058913G>A <br /> NG_009072.2:g.179924C>T <br /> LRG_587:g.179924C>T <br /> LRG_587t1:c.8253+39C>T

      ClinVarID:440406

      CAID:CA6401352

      gnomAD:0.10024

    1. In 1986, a preliminary report described a girl

      Case1: Female, 22 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Fig 1

      ParentalGenotype: The patient's parents revealed reduced concentrations of glycoprotein llb-Illa and were considered to be heterozygotes. See Fig 1

      CasePresentingHPOs: HP:0000421, HP:0000225, HP:0000132, HP:0000978

      (Severe epistaxis, gingival bleeding, menorrhagia, spontaneous bruising)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Platelets had much reduced alphaIIb3 when estimated by crossed immunoelectrophoresis

      PlateletAggregation: Platelet aggregation was absent with ADP, arachidonic acid, and collagen.

      CasePreviousTesting: Sequenced all exons and splice sites of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.1073G>A (p.Arg358His) and NM_000419.3:c.1234G>A (p.Gly412Arg)

      LegacyVariant: (p.Arg327His) and (p.Gly381Arg)

      ClinVar: 2896 and 381748

      CAiD: CA115839 and CA8603182

      gnomAD: MAF in the Latino population is 0.0001453 https://gnomad.broadinstitute.org/variant/17-42458406-C-T

      PreviouslyPublished: PMID: 3762006 proband is mentioned in this article

    1. The patient

      Case1: Female, 5 years old, Swiss (from Morocco)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected brother

      ParentalGenotype: Mother and father are heterozygous for the variant of interest

      CasePresentingHPOs: HP:0001250, HP:0001270, HP:0000967, HP:0001892

      (Seizures, retarded motor development, petechia, hemorrhagic diathesis)

      CaseHPOFreeText: Subepndymal hematomas, cortical tubera, hydrocephalus internus

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry protein expression results can be seen in Figure 1

      PlateletAggregation: Platelets failed to aggregate with ADP, collagen, or arachidonic acid; however, ristocetin induced platelet agglutination was normal

      CasePreviousTesting: Amplified DNA fragments containing exon 11 of the GPIIIa gene were purified by PCR preps DNA purification resin and wizard.

      Gene: ITGB3

      Variant: NM_000212.2:c.1702T>C (p.Cys568Arg)

      LegacyVariant: (p.Cys542Arg)

      ClinVar: N/A

      CAiD: CA400032350

      gnomAD: N/A

    1. Patient 2

      Case2: Female, 28 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type 1

      FamilyInfo: N/A

      ParentalGenotype: Parents were heterozygous for this mutation and did not show bleeding symptoms

      Note: There is parental consanguinity

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Severe haemorrhagia and haematomas associated with prolonged in vivo bleeding time

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis revealed 3.5 % of αIIbβ3 was detected on the platelet surface from patient 2.

      PlateletAggregation: Article states agonist-induced platelet aggregation and binding of exogenous fibrinogen was pathological, too but does not mention specific agonists used or response to ristocetin

      CasePreviousTesting: Molecular genetic analysis was done; however, no other information mentioned. In addition, the global proteome of highlight purified washed platelets was quantified by liquid chromatography-mass spectrometry and targeted MS-methods.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2374del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940267

      gnomAD: N/A

    1. Patient LD

      Case1: (Patient LD) Female, 3 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Fig 4 for family pedigree

      ParentalGenotype: Father is heterozygous for GC867-G and Mother is heterozygous for T882C (See Fig 4)

      CasePresentingHPOs: HP:0000967, HP:0031364, HP:0000978, HP:0000225

      (Petechiae, ecchymosis, bruising, gingival bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Fig 2A shows reduced expression (See Fig2A)

      PlateletAggregation: Platelets did not aggregate in response to ADP, epinephrine, or arachidonic acid and showed only shape change in response to collagen. Platelets did agglutinate with ristocetin.

      CasePreviousTesting: Genomic DNA was prepared from peripheral blood leukocytes and amplified by polymerase chain reaction (PCR) with Taq polymerase by using oligonucleotide primers from intronic flanking sequences of αIIb and β3. All exons of both genes were sequenced at least twice to exclude Taq errors.

      Gene: ITGB3

      Variant: NM_000212.2:c.863T>C (p.Leu288Pro) and NM_000212.2:c.847_848del

      LegacyVariant: (p.Leu262Pro)

      ClinVar: N/A

      CAiD: CA400024958 and CA8623068

      gnomAD: for c.847_848del https://gnomad.broadinstitute.org/variant/17-45364504-AGC-A

    1. The patient,

      Case1: (Patient JO) Female, 38 years old, Japanese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Parents shown Fig 6

      CasePresentingHPOs: HP:0000978, HP:000042, HP:0000132

      (Easy bruising, epistaxis, menorrhagia)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: Figure 6 shows surface expression

      Platelet Aggregation: Absent aggregation in response to ADP, epinephrine, collagen and thrombin however normal response to ristocetin

      CasePreviousTesting: Total cellular RNA was obtained, and aIIbb3 mRNAs were specifically amplified by reverse transcription PCR (RT-PCR) as previously described (41).

      Gene: ITGA2B

      Variant: NM_000419.3:c.575_576insGGACAA (went over with Shruthi)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940650

      gnomAD N/A

    1. 9-year-old boy

      Case1: Male, 9 years old,

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: One brother, with no signs of bleeding diathesis

      ParentalGenotype: Father is heterozygous for the c.2268C>T mutation and the mother is compound heterozygous with the c.2268C>T variant and c.2330C>T variant

      CasePresentingHPOs: HP:0000421 Epistaxis

      CaseHPOFreeText: Submucosal bleeding, hematomas, excessive achilles tendon bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: The patient's αIIbβ3 receptor count was estimated approximately 50% of that measured in a healthy age-matched control by quantitative flow cytometry

      PlateletAggregation: Complete absense of platelet aggregation in response to ADP, arachidonic acid, epinephrine, collagen

      CasePreviousTesting: Direct sequencing of the patients αIIb and β3 genes was perforemed

      Gene: ITGB3

      Variant: NM_000212.2:c.2248C>T (p.Arg750Ter)

      LegacyVariant: (p.Arg724Ter)

      ClinVar: 13564

      CAiD: CA123246 (p.Arg750Ter)

      gnomAD: N/A

    1. The patient

      Case1: Female, 21 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Blood samples collected from brother, no other information provided

      ParentalGenotype: Father heterozygous: NM_000419.3:c.258G>C and mother heterozygous: NM_000419.3:c.2334A>C

      CasePresentingHPOs: HP:0000421, HP:0000979

      (Epistaxis, purpura)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis and western blot analysis showed a remarkable reduction in aIIb b3 and aIIb, and a moderate reduction in b3 in the platelets of the patient (data not shown)

      PlteletAggregation: N/A

      CasePreviousTesting: Nucleotide sequences of aIIb cDNA and b3 cDNA amplified by reverse transcription polymerase chain reaction (RT-PCR) were analyzed

      Gene: ITGA2B

      Variant: NM_000419.3:c.258G>C (p.Leu86Pro) and NM_000419.3:c.2334A>C

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA500624524 and CA399796662

      gnomAD: N/A

    1. The patient is a 1‐year‐old female from Morocco

      Case1: Female, 1 year old, ethnicity not specified (patient from Morocco)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Her brother is asymptomatic. Her first cousin, (male) died as a result of some unknown bleeding disorder

      ParentalGenotype: Parents fully sequenced and

      CasePresentingHPOs: HP:0000967, HP:0000978

      (Petechia, bruising)

      CaseHPOFreeText: Mucocutaneous hemorrhages

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed less than 10% of ITGA2B and ITGB3 complexes

      PlateletAggregation: Platelet aggregation in response to ADP, thrombin, collagen and epinephrine was less than 10% of normal platelets and risotcetin induced platelet agglutination was normal

      CasePreviousTesting: Complete analysis of ITGA2B and ITGB3 coding sequences were performed (PCR)

      Gene: ITGA2B

      Variant: NM_000419.3:c.188G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8603528

      gnomAD: MAF in the European (non-Finnish) population is 0.000008803 http://gnomad.broadinstitute.org/variant/17-42466654-C-T

    1. Patient Osaka-12

      Case1: Female, 21 years old, Japanese (Named Osaka-12 in this study)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The substitution was inherited from her father. The molecular genetic defect inherited from her mother remains determined.

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Moderate mucocutaneous bleeding in childhood

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed revealed a significant reduction in the expression of αIIbβ3 on Osaka-12 platelets

      PlateletAggregation: Absent platelet aggregation in response to ADP, epinephrine, and collagen but a normal response to ristocetin

      CasePreviousTesting: To identify the molecular genetic defect for the proband of interest, all coding regions of ITGA2B and ITGB3 cDNA amplified by RT-PCR were analyzed

      Gene: ITGA2B

      Variant: NM_000419.3:c.520T>C (p.Tyr174His)

      LegacyVariant: (p.Tyr143His)

      ClinVar: N/A

      CAiD: CA399805805

      gnomAD: N/A

    1. The proband is a 35-day old female infant born from a twin delivery.

      Case1: Female, 35 day old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The proband’s mother and father carry heterozygous c.512delC and c.1686delG mutations, respectively. Other parameters for parents are shown in Table 1.

      CasePresentingHPOs: HP:0031364, HP:0000967

      (Ecchymosis, petechiae)

      CaseHPOFreeText: Large parietal and cervical cephalohaematoma, severe anemia

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry of platelet surface antigens revealed the absence of the αIIbβ3 complex.

      PlateletAggregation: Prolonged closure time at PFA-100, absent ADP, adrenaline, collagen induced platelet aggregation, and ristocetin induced platelet aggregation at the lower limit of normal

      CasePreviousTesting: Sequencing of ITGA2B and ITGB3 genes showed that proband is compound het.

      Gene: ITGA2B

      Variant: Can not conclusively determine if c.481delC and c.1654delG are the variants intended by the authors based on the available information.

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: N/A

      gnomAD: N/A

    1. Case#: Downes_2019_BSS, male, age unknown, South-Asian ancestry reported

      DiseaseAssertion: BSS

      FamilyInfo: NR

      ParentalGenotype: NR

      CasePresentingHPOs: NR

      PlateletAggregation: NR

      CaseHPOFreeText: NR

      CaseNotHPOs:

      CaseNotHPOFreeText:

      ProteinExpression: NR

      CasePreviousTesting:

      GenotypingMethod: HTS panel described in supplementary table 3

      PreviouslyPublished:

      Gene: ITGA2B

      Variant: homozygous c.1005_1013del (p.His335_Leu338delinsGln)

      HGVS: NM_000419.5(ITGA2B):c.1005_1013del

      ClinVarID: 626948

      CAID:

      gnomAD: not found in v.2.1.1

      MultipleGeneVariants:

    1. Thepatient(M.S.)

      Case1: (M.S) Female, 19 years old, Caucasian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The mutation has been inherited from proband's parents who are heterozygous for the same mutation the proband has.

      CasePresentingHPOs: HP:0000978 (Bruising)

      CaseHPOFreeText: Intracerebral hematoma

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Fig 4 for flow cytometry analysis of protein expression

      PlateletAggregation: Absence of platelet aggregation in response to all agonists tested i.e. ADP, collagen, platelet activating factor acether thrombin, and arachidonic acid; however, ristocetin induced platelet aggregation was normal

      CasePreviousTesting: Sequenced patient's GPIIIa exons encompasing a highlight conserved reion of GPIIIa.

      Gene: ITGB3

      Variant: NM_000212.2:c.718C>T (p.Arg240Trp)

      LegacyVariant: (p.Arg214Trp)

      ClinVar: 13555

      CAiD: CA123228

      gnomAD: MAF in the East Asian population is 0.00005437 http://gnomad.broadinstitute.org/variant/17-45363729-C-T

    1. The proband was a 2‐year‐old man

      Case1: Male. 2 years old, Gypsy

      DiseaseAssertion: Glanzmann's thrombasthenia

      FamilyInfo: See Fig 3 and 4 for family pedigree

      ParentalGenotype: Parents are heterozygous for the variant of interest

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mucocutaneous hemorrhages and spontaneous bruising

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Protein expression results can be found in Table 1

      PlateletAggregation: Platelets aggregated in response to agonists although they reacted positively to ristocetin (See Case History section for this sentence

      CasePreviousTesting: Analyzed the amplification of products of all exons of GPII and their intronic flanking regions by single stranded conformational polymorphism analysis. All GPIIIa exons were also analyzed by SSCP and gave results identical to controls

      Gene: ITGA2B

      Variant: NM_000419.3:c.1063G>A (p.Glu355Lys)

      LegacyVariant: N/A

      ClinVar: 2899

      CAiD: CA115844

      gnomAD: MAF in the European (non-Finnish) population is 0.00001978 http://gnomad.broadinstitute.org/variant/17-42461008-C-T

    1. A 30‐year‐old male patient

      Case#: Patient B, Male, Age 30, Chinese

      Disease Assertion: VWD3

      FamilyInfo: Consanguineous marriage between parents. Parents had 2 daughters and a son. One daughter died (1 year old) due to bleeding disorder. Mother's VWF:Ag 58% and VWF:RCo 36%. Family pedigree in Figure 2 (a). Both parents were heterozygous carriers of the variant.

      Parental Genotype: Both Heterozygous

      CasePresentingHPOs: HP:0003645

      (Prolonged partial thromboplastin time)

      CaseHPOFreeText: Hematoma in the lower extremity, VWF:Ag: 0.5%, VWF:RCo: 0.1%, FVIII:C 1.2%, APTT: 72.0 s

      CaseNotHPOs:

      CaseNotHPOFreeText: PT: 13.6 s, TT: 14.9s

      Protein Expression: N/A

      CasePreviousTesting: NGS targeting all exons and covered F8, F9, and VWF genes; and Sanger Sequencing

      Gene: VWF

      Variant: NM_000552.4:c.6450C>A

      ClinVar: N/A

      CAID: CA383491381 CAID

      gnomAD:N/A

    2. A 23‐year‐old female

      Case#: Patient A, Female, Age 23, Chinese

      Disease Assertion: VWD3

      FamilyInfo: Family pedigree in figure 1(a). Consanguineous marriage between parents. Parents had a boy who died (1 year old) due to heavy nose bleeds. Parents were heterozygous carriers for the variant.

      Parental Genotype: Both parents were heterozygous

      CasePresentingHPOs: HP:0000132, HP:0003645, HP:0008151

      (Menorrhagia, Prolonged partial thromboplastin time, Prolonged prothrombin time)

      CaseHPOFreeText: Scalp hematoma, FVIII:C: 1.3%, VWF:Ag: 3.6%, VWF:RCo: <1.0%, PT: 15.9 s, APTT: 62.7 s

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: TT: 14.9 s

      Protein Expression: N/A

      CasePreviousTesting: NGS targeting all exons and covered F8,F9, and VWF genes; and Sanger Sequencing

      Gene: VWF

      Variant: NM_000552.4(VWF):c.4696C>T (p.Arg1566Ter)

      ClinVar:100382 ClinVarID

      CAID: CA228639

      CAID

      gnomAD: MAF of 0.00001762 (2/113480 alleles) in the European (Non- Finnish) population.

      gnomAD

    1. III-1

      III-1, Female 10 years old

      disease assertion: VWD

      **positive family history **

      Parental Genotype: each has heterozygous, 3251G>A

      CasePresentingHPOs: CaseHPOFreeText: BS 4, VWF Ag:0.38, *VWF:GPIbM:0.15,VWF:CB:0.13, VWFpp :0.76, FVIII:C:0.10

      CaseNOTHPOs:* N.a.

      CaseNOTHPOFreeText: n.a.

      CasePreviousTesting: *GenotypingMethod: Sanger seqencing;

      *PreviouslyPublished:n.a.

      Gene:VWF Variant:c.3251G>A*

      *HGVS:NM_000552.5:c.3251G>A

      • *ClinVarID:Variation ID: 626952

      *CAID:n.a.

      *gnomAD:n.a.

    1. older patient (index patient)

      Case1: 44 year old male

      DiseaseAssertion: Dilated cardiomyopathy

      FamilyInfo: Affected brother, two sisters and both parents unaffected, parents denied consanguinity and were assumed to be second cousins

      CasePresentingHPOs: HP:0003704, HP:0009060, HP:0000218, HP:0000276, HP:0000819, HP:0003691

      "Scapuloperoneal weakness, scapular muscle atrophy, high palate, long face, Diabetes mellitus, Scapular winging

      CaseHPOFreeText: decreased cardiac systolic function, clinical symptoms of cardiac failure at 44 years old, left ventricular systolic and diastolic dysfunction, exertional dyspnoea, ymmetrical wasting of the sternocleidomastoideus, trapezius, supraspinatus, pectoralis, deltoid, triceps, biceps, paravertebral and tibialis muscles at age 56

      CasePreviousTesting:

      GenotypingMethod: genome scan using 730,000 single nucleotide polymorphism (SNP) markers. Sequence analysis for the last four MYH7 exons

      Variant: NM_000257.4:c.5458C>T

      ClinVar: 181282

      CAID: CA016126

      gnomAD: https://gnomad.broadinstitute.org/variant/14-23884305-G-A

      0.00008011 African

    1. 84

      Case#: 84, Gender N/A, 6 months old when diagnosed, Asian

      DiseaseAssertion: Pompe disease

      FamilyInfo: Both parents were tested for variants in GAA

      CasePresentingHPOs: N/A

      CaseHPOFreeText:N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: The patient did not present any symptoms, diagnosed was made based on the predicted impact of the variant by PolyPhen-2

      CasePreviousTesting: The GAA gene was sequenced using NGS and resequenced for confirmation using Sanger.

      Dried Blood spot test found an GAA activity of 3.8 pmol/h/disk with a reference value of 6.5 pmol/h/disk

      enzyme activity in fibroblast was recorded to be 3.0 nmol/h/mg protein.

      Variants: Variant1: (Two mutated alleles with heterozygous mutations)

      Variant1.1: NM_000152.5(GAA):c.752C>T (p.Ser251Leu)

      ClinVar: 346310

      CAID: CA8815007

      gnomAD: Highest population MAF = 0.002234 (East Asian)

      Variant1.2: NM_000152.5(GAA):c.761C>T (p.Ser254Leu)

      ClinVar: 330447

      CAID: CA8815009

      gnomAD: Highest popu;ation MAF= 0.002235 (East Asians)

      Variant2: C.1244C>T

      ClinVar: N/A

      CAID: N/A

      gnomAD: N/A

      ParentalGenotype: The c.752C>T+c.761C>T and c.1244C>T of subject ID 84 were derived from mother and father, respectively

      PreviouslyPublished:N/A